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Abstract
Staphylococcus aureus and its small colony variants (SCVs) are commonly isolated from
the lungs of cystic fibrosis (CF) patients. Although studies have suggested that cystic fibrosis
transmembrane regulator (CFTR)-deficient macrophages are diminished in their ability to kill
intracellular pathogens, whether this is true for CFTR-deficient macrophages infected with S.
aureus or its SCVs is unknown. I employed gentamicin protection and eFluor-670-based
proliferation assays to assess the intracellular replication of S. aureus in CFTR inhibitor treated
THP-1 and primary human macrophages, and in primary macrophages derived from CF patient
blood. My work shows that the susceptibility of CFTR-deficient macrophages to the intracellular
growth of wildtype S. aureus USA300 and its SCVs is similar to control macrophages.
Importantly, my work demonstrates that SCVs proliferate intracellularly, suggesting that they
overcome their auxotrophy through an unknown mechanism. Due to the increasing prevalence of
antibiotic-resistant S. aureus, a better understanding of pathogen-host interactions is vital.

Keywords: Staphylococcus aureus, macrophage, infection, cystic fibrosis, small colony variant,
SCV, menD, hemB, hemin, menadione
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Summary for Lay Audience
Staphylococcus aureus is a human bacterial pathogen that is frequently isolated from the
lungs of cystic fibrosis (CF) patients. S. aureus’ multi-drug resistance complicates the treatment
of CF patients who are repeatedly infected. Additionally, small colony variants (SCVs) of S.
aureus which are slow-growing forms of the bacterium, are found in the CF lung and are said to
result in prolonged and recurrent infection. S. aureus infections can result in lung dysfunction,
which is the most common cause of morbidity and mortality in CF patients. Although patient lungs
are typically highly inflamed and populated by white blood cells, these white blood cells are not
able to control the presence of S. aureus. I investigated whether CF patient macrophages, an
important type of white blood cell involved with the removal of pathogens, are less capable of
killing this bacterium when compared to healthy macrophages, and whether SCVs differ from
wildtype S. aureus in how they interact with macrophages. My work showed that in a subset of
CF model macrophage populations, S. aureus and its SCVs are capable of surviving and replicating
inside macrophages, as they do in healthy macrophage populations. These observations are
important because they suggest that CF macrophages are not especially susceptible to infection by
S. aureus. Interestingly, my findings demonstrate that SCVs can replicate inside macrophages
despite being unable to produce the nutrients they require for growth, suggesting that they acquire
the energy required for their growth through an unknown mechanism. This work enhances our
understanding of the host-staphylococcal interactions which may occur in the context of CF and
is therefore important for the discovery of novel treatments for staphylococcal infections in CF
patients.
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Chapter 1: Literature Review
1.1

The innate immune system: overview

The innate immune system is the host’s initial defense strategy against invading pathogens such
as viruses, bacteria, fungi, and parasites. The innate immune defenses involve non-specific and
rapid protection against invasion by pathogens through physical, chemical, and cellular means.
Physical barriers include the skin, tears, and mucosal surfaces, which work to keep pathogens from
entering host cells (1, 2). As a physical barrier, the skin prevents pathogen invasion, retains
moisture, and protects against harmful agents. The skin is comprised of three layers, the outermost
epidermis, the middle dermis, and the innermost subcutaneous tissue. Keratinocytes mature as they
are pushed upward through the layers of the epidermis and displace their cytoplasmic contents
with the fibrous protein, keratin, then harden and die (3). This process, called keratinization, forms
a tough physical barrier of cornified cells that prevent pathogen invasion into the host’s underlying
cells and tissues (3).
As a chemical barrier the skin’s pH is around 5.4 to 5.9 which makes it inhospitable to most
potential pathogens, but hospitable to commensal bacteria like Staphylococcus epidermidis (4).
This low pH is maintained by the release of lactic acid and electrolytes through sweat glands, as
well as the production of fatty acids within the epidermis (5, 6). Additionally, secreted hydrophobic
lipids and epithelial cell-cell contact molecules prevent the entrance of foreign liquids and particles
(7–9). These qualities also reduce the moisture in the epidermis, thus making it inhospitable for
microbial survival. Lipid rich sebum is produced by sebaceous glands, and secreted around hair
follicles to prevent the entry of pathogens into the internal layers of the skin (10). Moreover,
keratinocytes and epithelial cells produce antimicrobial peptides such as dermicidin, cathelicidins
and β-defensins, which work by disrupting microbial cell membranes (8, 11–13). Various other
immunocompetent cells reside within the epidermis and dermis, such as Langerhans’ cells, dermal
dendritic cells, mast cells, and T cells (12). During an infection, keratinocytes release many
cytokines and chemokines in order to recruit more immune cells to the site of infection (12). For
example, through upregulating the CXCL1 and CXCL9 chemokines,
neutrophils to the epidermis (14).
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keratinocytes recruit

In addition to the protection provided by the skin, innate immune strategies are in place to prevent
the entry of pathogens into host cells through mucus membranes, such as the eyes, respiratory
tract, and gastrointestinal tract. A strategy used by mucosal tissues to reduce microbial colonization
is through the secretion of mucus. Mucus is incredibly important for the innate immune defenses
across many internal epithelial surfaces (2). In a healthy pulmonary environment, mucus
overlaying respiratory airway surfaces can trap extracellular pathogens (15). Through mucociliary
action and coughing, this mucus can be removed by the body, thus clearing the airway of the
trapped pathogens (15). In addition, tears physically remove microbes from internal and external
host tissues through their washing action (16). Tears also contain many antimicrobial products,
one of which is lysozyme (16). Lysozyme is a highly conserved bacteriolytic enzyme which
hydrolyzes the peptidoglycan in bacterial cell walls, and can also be found in saliva and other
bodily secretions (1, 17). Another example of an innate immune strategy employed by mucosal
tissues is stomach acid. The stomach’s acidic environment is fatal to many potential pathogens
that can be ingested during food and beverage consumption (18). Importantly, this acidity also
selects for commensal microorganisms that are important for maintaining the health of the
gastrointestinal tract (18).
When chemical and physical barriers are breached, the innate immune system employs the
complement system to opsonize pathogens for enhanced phagocytosis and cytolytic elimination
(1, 2, 19). The complement system can be activated through three mechanisms. The classical
activation pathway interacts with the adaptive immune system as it is initiated when antibodybound pathogens bind to complement proteins (19). The lectin pathway similarly does not require
an antibody-antigen complex, but instead recognizes pathogen surface sugars to initiate its
response (Fig. 1A) (19). Finally, the alternative complement pathway is similar to the classical
pathway, but it does not require the presence of an antibody-antigen complex for initiation (Fig.
1A) (19). Instead, this pathway is activated through a series of serine protease complement
cleavage events (Fig. 1A) (19). All three activation processes lead to a cascade of protein
interactions which result in the activation of phagocytes (explained in detail in a later section), and
formation of a membrane attack (C5b-9) complex that forms pores on a pathogen’s cell membrane
that ultimately cause cell lysis (Fig. 1B-C) (19).

2

Cell-mediated defenses are important for the eradication of pathogens during the early stages of
infection. Innate immune cells such as neutrophils, dendritic cells, and macrophages are in part
responsible for recognizing pathogens early, and subsequently activating signaling pathways that
will act to eradicate them (1). Pathogens can express pathogen-associated molecular patterns
(PAMPs), which are often required components in their life cycles (20). PAMPs include lipids,
proteins, carbohydrates, and nucleic acids that are recognized by pattern recognition receptors
(PRRs) expressed by the immune cells mentioned above (20). This subsequently activates
inflammatory response pathways like the mitogen-activated protein kinase (MAPK), Janus kinase
(JAK)-signal transducer and activator of transcription (STAT), and nuclear factor kappa-B (NFκβ) pathways (21). These pathways differentially promote the production of pro-inflammatory
cytokines and chemokines that increase vasculature permeability and recruit additional immune
cells from the blood, including neutrophils and monocytes (21).
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Figure 1. A schematic overview of the complement system. A) The classical pathway is
activated when an antigen-bound antibody (IgG/IgM) binds to the C1 complex. This complex is
comprised of two molecules of complement component 1s (C1s), two molecules of complement
component 1r (C1r), and one molecule of complement component 1q (C1q). The mannan-binding
lectin pathway uses mannan-binding lectin (MBL) to bind to mannose residues on the cell-surface
of microbes. MBL (homologous to C1q) forms a complex with two serine proteases, MASP-1 and
MASP-2 (homologous to C1s and C1r). The alternative pathway is initiated when the thioester
bond in plasma C3 is spontaneously hydrolyzed. This alters the conformation of the protein so that
plasma factor B may bind to it. Plasma factor D, a protease, binds and cleaves factor B into Ba and
Bb (not shown). When Bb forms a complex with C3(H2O), it converts C3 to C3b and C3a (not
shown). C3b can then bind microbial plasma membranes, allowing it to avoid hydrolysis. B) In
the classical and lectin pathways, the activated C1 and MLB complexes first cleave C4 into C4a
and C4b, and then cleave C2 into C2a and C2b. A C3b convertase is formed when C2a and C4b
bind one-another on the microbial plasma membrane (C4b,C2a). In the alternative pathway, the
membrane bound C3b is bound by factor B. Factor B is then bound and cleaved by factor D to
form Ba and Bb; the Bb remains bound to the C3b to form a C3b convertase (C3b,Bb). These C3b
convertases cleave C3 into C3a and C3b; C3b’s opsonize the plasma membrane of the microbe as
they accumulate on the surface. C) In the classical and lectin pathways, C4b,C2a binds C3b to
form the C5 convertase (C4bC2aC3b). In the alternative pathway, C3bBb binds a second C3b to
form the C5 convertase (C3b2Bb). The C3b components of these C5 convertases bind C5, and the
C2a or Bb cleave C5 into C5a and C5b. C5b then binds C6 and C7 to form the C5b,6,7 complexes
which bind to the microbial cell membrane. C8 binds to the complex and inserts into the cell
membrane. Next, 10-16 C9 molecules bind to the complex and polymerize to form a membrane
pore, otherwise known as the membrane-attack complex (22). Created with BioRender.com.

1.1.1 Macrophages
Macrophages are resident lymphoid and non-lymphoid tissue leukocytes that have a range of
specialized immune functions (Table 1). They are a part of a subgroup of leukocytes called myeloid
cells, which arise through the process of myelopoiesis (23). Myelopoiesis can be generalized as
the process which produces bone marrow and all of its associated cells. This process begins in the
yolk sac, and during gestation monocyte progenitors colonize different organs (23). Various
specialized tissue resident macrophages arise throughout the different stages of myelopoiesis,
before and after birth (23). After birth, bone marrow-derived monocytes circulate to various tissues
to replenish tissue resident macrophages (23, 24). Additionally, monocytes recruited to sites of
infection and injury through inflammation, can differentiate into macrophages (23, 24).
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Table 1. List of various tissue-resident macrophages and their specific unique functions.
Macrophage

Location

Unique function

Kupffer cells

Liver

Removal of pathogens, toxins, erythrocytes, cellular debris found
in the blood. Metabolizing lipids. Recycling heme, bilirubin, and
iron. (25, 26)

Microglia

Brain

Regulation of neurons and progenitors. Monitoring synaptic
function. Neural development and adult neurogenesis. Synapse
development, stripping, and homeostasis. (27)

Osteoclasts

Bone

Bone resorption during growth remodelling. Osteoimmunology.
(28)

Alveolar

Lung

Removal of respiratory pathogens and cellular debris. (29)

Heart

Heart;

Facilitation of electrical conduction. (30)

vasculature
Adipose

Adipose

Adipocyte remodelling and clearance. Lipid clearance and

tissue-

tissue

storage. Promote insulin resistance and sensitivity. Exophagy.

associated
Langerhans

Promote angiogenesis. (31)
Skin

Removal of skin pathogens. (32)

Intestines

Intestinal homeostasis and remodelling. Defense against enteric

cells
Intestinal
lamina

pathogens. Tolerance of microbiota. (33)

propria
Marginal
zone and

Spleen

Interact with adaptive immunity to enhance eradication of bloodborne pathogens. (34)

marginal
metallophilic
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Red pulp

Spleen

Recycle senescent erythrocytes. (34)

As professional phagocytes, macrophages ingest and eradicate foreign particles and pathogens
through a receptor-mediated process called phagocytosis (described below). Macrophage function
is similarly activated in response to a variety of antigens and PAMPs; thus, they serve an integral
role for cell-mediated innate immunity. Upon phagocytosis, macrophages can present antigens on
their major-histocompatibility complexes (MHCs), to be recognized by cells that are a part of the
adaptive immunity, such as CD4+ T-helper cells (35). Therefore, as antigen-presenting cells, they
facilitate a crucial link between the innate and adaptive immunity. Simultaneously, through the
production of cytokines and chemokines, macrophages can either maintain or resolve
inflammation during immune responses (36). Therefore, they are important regulators of the
inflammatory response.
Macrophages can be activated by their environment to enhance their specificity of response to
tissue damage or pathogen invasion. They are broadly categorized by their placement on a
continuum between two different polarization states. M1 classically activated macrophages secrete
pro-inflammatory cytokines and microbicidal effectors, and exhibit upregulated inducible NO
synthase that increases antimicrobial reactive-oxygen species (ROS) (37–40). These inflammatory
cytokines activate T-cells, induce inflammation, and promote complement-mediated phagocytosis
(37–41). Macrophage maturation occurs in the presence of macrophage colony-stimulating factor
(M-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF) cytokines, which differ
in the morphological cytoskeletal arrangements that they stimulate within the macrophage (40).
M-CSF derived human macrophages are more spindle-shaped, while GM-CSF derived human
macrophages are more circular and elongated (40). After maturation, macrophages can be
activated by additional cytokines, to arrive at various phenotypes along the continuum of
polarization (40). M1 macrophages typically arise when M-CSF or GM-CSF matured
macrophages are treated with interferon-gamma (IFN-γ), tumor necrosis factor (TNF), and
lipopolysaccharide (LPS) (37–40). M2 alternatively activated macrophages are anti-inflammatory
and work to facilitate tissue repair, and regulate inflammation through anti-inflammatory cytokine
production (40). M2 macrophages arise when M-CSF or GM-CSF matured macrophages are
7

treated with interleukin-10 (IL-10) (40). M2 macrophages are also activated by signs of tissue
damage, such as apoptotic cells, to assist with tissue repair and regeneration (37–40).
1.1.2 Phagocytosis
As professional phagocytes, macrophages prevent the spread of infection by ingesting and
eliminating invading pathogens through the process of phagocytosis. Phagocytosis is also
important for eliminating apoptotic host cells, a process called efferocytosis (not covered in this
literature review). Phagocytosis can be described by four major steps (Fig. 2). First, the phagocyte
must recognize and bind the target of interest, which can include dead or dying cells, foreign
particles, or pathogens. Second, the phagocyte must initiate a signaling cascade to operate the
internalization of the target particle. Third, a phagosome, or cytoplasmic vacuole containing the
particle, forms from a portion of the phagocyte’s plasma membrane and matures. And finally, a
lysosome fuses with the mature phagosome to form a phagolysosome, an internal vacuole that
eradicates the particle by using an arsenal of chemical agents. In this section, I provide a brief
overview of phagocytosis by summarizing multiple comprehensive reviews.
Phagocytosis begins with receptor-mediated recognition of opsonized particles or direct
recognition of the PAMPs (20, 42, 43). Non-opsonic receptors include integrins which can bind
target lectins (e.g. type 1 fimbriae), RGD-containing proteins (e.g. filamentous hemagglutinin),
and glycolipids (e.g. lipoteichoic acid) (44). Other examples of non-opsonic receptors include the
CD206 mannose receptor which binds mannan, Dectin-1 (CLEC7A) which binds β1,3-glucan, and
CD14 which binds lipopolysaccharide-binding protein (42). Opsonic receptors include receptors
that recognize particles opsonized with complement and antibodies (42). Complement receptor
(CR)-mediated phagocytosis relies on a family of macrophage CRs that preferentially bind to C3b
and its associated fragments (45). The Fc receptor family is a group of plasma membrane receptors
involved with phagocytosis, endocytosis, and granule release (46). Macrophages contain Fcγ
receptors, which bind to the Fc portion of IgG, and initiate a phagocytic signaling cascade through
immunoreceptor tyrosine based activation motifs (ITAMs) and immunoreceptor tyrosine based
inhibitory motifs (ITIMs) (46).
The next step in phagocytosis is the initiation of the signal that leads to the internalization of the
target particle. Phagocytosis can result from multiple different receptor-initiated cascades being
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activated simultaneously (42). Each phagocytic receptor initiates a unique signaling cascade, some
of which are more understood than others (42). Since Fcγ is one of the better understood receptormediated pathways, I will use this as a model to describe the remaining steps of phagocytosis.
Upon receptor binding, the ITAM tyrosines are activated through phosphorylation by Src family
kinases, which produces Src homology 2 (SH2) binding sites that are important for the subsequent
recruitment of Syk tyrosine kinases (46). After the phagocytic signal has been initiated, pseudopod
formation through actin remodelling begins at the site of receptor binding, to produce the
phagocytic cup (46). This actin remodelling results from the action of Rho GTPases including Rac
and CDC42, and many other signal proteins (46). Lipid-modifying enzymes such as
phosphatidylinositol kinases (like phosphatidylinositol 3-kinase, PI3K) and phospholipases, and
their associated derivatives (like Phospholipase A, PLA) are also associated with the formation of
the phagocytic cup (46).
The formation and maturation of the phagosome comprises the next step of phagocytosis. The
phagocytic cup is pulled into the cytosol, and the plasma membrane is pinched off by myosin
purse-string contractions to form the phagosome (42, 43, 46, 47). After formation, the phagosome
undergoes maturation from an early to late phagosome; during this time the membrane and
contents are altered (42, 43, 48). The early phagosome envelopes the pathogen tightly and
undergoes many fusion events with endosomal vesicles and the plasma membrane which facilitates
the recycling of membrane material (42, 43, 49). Motor-driven vesicular traffic, fusion, and fission
to and from the phagosome is mediated by the small GTPase, Rab5, which functions through the
use of multiple effectors (42, 43, 50). Rab5 recruitment is not fully understood, but it is known to
be higher in the phagosomal membrane than in the plasma membrane (42). Rab5 regulates mVps34
activation and localization to the phagosomal membrane, where it works to produce
phosphatidylinositol 3-phosphate [PI(3)P] (42). As PI(3)P accumulates on the phagosomal
membrane, it primes the phagosome for further maturation steps (42).
EEA1, another Rab5 effector, is recruited to the phagosomal membrane where PI(3)P is bound on
the cytosolic leaflet (42). Here, EEA1 interacts with a soluble N-ethylmaleimide-sensitive factor
attachment protein receptor (SNARE), syntaxin 13, to facilitates endosomal fusion events (42).
Rab-coupling protein bound to Rab4 or Rab11 regulates membrane recycling; for example,
transferrin receptors present on the nascent phagosomal membrane are trafficked back to the
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plasmalemma as the phagosome matures (42). Eps15 homology domain proteins (EHDs) and
GTPase adenosine ribosylation factor (COPI) similarly recycle phagosomal proteins back to the
plasmalemma (42). Throughout phagosome maturation, V-ATPases on the phagosomal membrane
progressively acidify the lumen through facilitating the influx of protons; as a result the early
phagosome has a slightly acidic pH of between 6.1 to 6.5 (42, 43, 51). As the phagosome
maturation enters the intermediate phase, intralumenal vesicles (ILV) form through the
invagination of the phagosomal membrane, to traffic post-translationally modified membraneassociated cargo towards degradation (42). This invagination is regulated by endosomal sorting
complex for transport (ESCRT) proteins (42).
The late phagosome is defined by its absence of recycling proteins, which are removed during the
early phagosomal stage (42). A marker commonly associated with the late phagosome is the Rab7
small GTPase, which eventually replaces the Rab5s that are characteristic of the early phagosome
(42, 43). Rab7 facilitates the trafficking of the phagosome in a retrograde fashion, by interacting
with proteins that connect the membrane to dynein-dynactin motor complexes (42, 43, 52). Rab7
effectors include Rab7-interacting lysosomal protein (RILP) and oxysterol-binding protein-related
protein 1 (ORPLI), which work together to associate with motor dynactin/dynein to facilitate
vesicular trafficking and lysosomal fusion (42). The removal of Rab5 and the recruitment of Rab7
to the phagosomal membrane is facilitated by Mon1, a protein recruited to the earlier phagosome
(42). Mon1 interacts with HOPS, a protein complex also tethered to the phagosomal membrane,
in order to facilitate the Rab conversion (42).
Additionally, the lumenal pH is approximately between 5.5 and 6.0, as a result of its accumulation
of V-ATPases (42, 43). The late phagosome also accumulates lysosomal-associated membrane
proteins (LAMPs) which are glycosylated integral membrane proteins, required for preserving
lysosomal membrane integrity, Rab7 recruitment, and acquisition of microbicidal elements (42).
Maturation of the phagosome is also due to repeated remodeling by phagosome recycling and
multivesicular body (MVB) formation (42). This allows for the accumulation of tetraspanin protein
CD63 and lipid LBPA.
The final stage of phagocytosis occurs when the late phagosome fuses with lysosomes, a process
mediated by Rab7 (42, 43, 53, 54). The phagolysosome lumen is highly acidic, with an
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approximate pH of 4.5 due to its increased V-ATPase accumulation and lowered proton leakage
(42, 43). The phagolysosome also contains cathepsins, hydrolases, and antimicrobial peptides
accumulated through the various remodelling steps during maturation (42). The phagolysosome is
microbicidal in part due to the respiratory burst (55). The respiratory burst is the rapid release of
reactive oxygen species (ROS), like superoxide and hydrogen peroxide (55). These ROS are
produced by NADPH oxidases that are recruited to the phagolysosome (55). These oxidases, either
Phox or NOX2, transport electrons into the phagolysosome which are then used to reduce oxygen
into superoxide anion (55). ROS can damage the bacterial cells through disrupting bacterial
biomolecules, such as oxidizing iron-sulfur clusters (55). When these clusters are oxidized, they
release iron and this iron reacts with hydrogen peroxide to damage even more biological
molecules, such as DNA (55).
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Figure 2. A schematic overview of phagocytosis. Phagocytosis is the cellular process of
recognizing a target particle and ingesting it for degradation. As shown, phagocytosis relies on the
formation of a phagosome and subsequent maturation of the phagosome. During maturation, the
phagosomal lumen becomes increasingly acidic, and is continually remodeled through endosomal
fusion and fission events. The late phagosome fuses with a lysosome to form the phagolysosome,
an organelle primed with microbicidal factors which work to eradicate the internalized target
particle. Acronyms: early endosome (EE), recycling endosome (RE), multivesicular body (MVB),
trans-golgi network (TGN), transferrin receptor (TfR), endosomal sorting complex for transport
(ESCRT), intraluminal vesicles (ILV), Rab7-interacting lysosomal protein (RILP), oxysterolbinding protein-related protein 1 (ORPLI), lysosomal-associated membrane proteins (LAMP1/2),
NADPH Oxidase (NADPH Ox). This schematic was adapted from the information and figures
published in a comprehensive phagocytosis review (42). Created with BioRender.com.

1.1.3 The microbicidal environment of the phagosome
As mentioned above, the phagosomal lumen becomes increasingly microbicidal throughout its
maturation which is partly due to the action of V-ATPases. As acidity increases, the growth and
survival of some pathogens is hindered (42, 43, 56). Additionally, this acidic environment is
optimal for many hydrolytic enzymes present in the phagosome. The electrochemical gradient
produced by V-ATPases, also facilitates the efflux of microbial nutrients out of the phagosome,
effectively starving intraphagosomal pathogens of nutrients (42, 43). Natural resistance-associated
macrophage protein 1 (NRAMP1) is recruited to the phagosomal membrane during phagocytosis,
and facilitates the active efflux of divalent cations out of the phagosome (42, 43, 57, 58). These
cations are essential for microbial growth processes; therefore, their depletion hinders microbial
survival and replication. The phagosomal environment is also highly toxic to pathogens that are
susceptible to reactive oxygen and nitrogen species produced by the NOX2 NADPH oxidase and
the NOS2 inducible nitric oxide synthase, respectively (42, 43). These reactive species can
inactivate proteins, alter lipids, and damage DNA within the microbes, therefore inhibiting their
replication (42, 43, 59–62). The phagosome also contributes to the eradication of pathogens
through the use of various antimicrobial proteins and peptides that either prevent intracellular
growth or directly disrupt pathogen survival (42, 43). The phagolysosome contains lysozyme,
which hydrolyzes the β(1-4) glycosidic linkages in the peptidoglycan layers of Gram-positive
bacteria

(42, 43). Cationic antimicrobial peptides are also present in the phagolysosome; for

example, defensins work to permeabilize bacterial outer membranes by forming membrane pores
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that result in the diffusion of essential nutrients and ions (42, 43). Additionally cathepsins, a family
of serine, cysteine, and aspartate proteases, are found in the lysosome and the phagolysosome (42,
43). These proteases facilitate the degradation of the internalized pathogen.
1.1.4 Bacterial defenses against the macrophage
Bacteria employ many different defenses against the macrophage’s immune responses. One
strategy entails the perturbation of antibody-mediated or complement-mediated host defenses, to
avoid phagocytic uptake. For example, Streptococcus pyogenes expresses a Streptococcal
pyrogenic exotoxin B (SpeB) endoprotease which cleaves host immunoglobulins, and therefore
blocks IgG-mediated phagocytosis (63). Additionally, S. aureus produces protein A which binds
the Fc region of immunoglobulins to inhibit opsonophagocytosis (64). Certain bacterial species
are known as professional intracellular pathogens because they are capable of altering
phagocytosis or escaping phagosomes in order to survive and replicate. For example, Listeria
monocytogenes produces exotoxins which allow it to do this (65). One such exotoxin is
Listeriolysin O (LLO) which produces pores in the phagosomal membrane to disrupt the ion
gradient of the phagosomal lumen and ultimately results in the degradation of the membrane (66).
Phosphatidylinosistol-specific phospholipase C (PlcA) and the broad-range phospholipase C
(PlcB) have overlapping roles in mediating the phagosomal escape by cleaving polar heads of
membrane phospholipids (67). L. monocytogenes is then able to escape the phagosome and
replicate within the cytosol of the host cell (66). Finally, bacteria can also employ strategies to
evade eradication when inside the phagosome, allowing for intraphagosomal survival and growth.
For example, S. aureus expresses catalase and superoxide dismutase to counteract the reactiveoxygen species present in the phagosome (68). S. aureus can also overcome the nutrient-depleted
environment of the phagosome by employing iron scavenging molecules called siderophores, to
accumulate and store iron for their growth (69). As it is the subject of this thesis work, S. aureus
will be discussed at length in following sections.

1.2

Staphylococcus aureus

S. aureus is an opportunistic Gram-positive bacterium that can be acquired from the community
or nosocomial environments (70). S. aureus colonizes the nares of thirty percent of the population
of healthy individuals world-wide (70). Among other sites, colonization can also occur in the skin,
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gastrointestinal tract, and throat. S. aureus transmission can occur through skin-to-skin contact or
through contact with fomites (70). In healthy individuals, risk factors such as chronic skin infection
and smoking can increase the frequency of nasal colonization (70). S. aureus can cause invasive
disease in the form of tissue infection and bacteremia (70). The ability of S. aureus to infect almost
all tissues of the human body can be attributed to its arsenal of virulence factors, which will be
explained in detail in the next section.
Alarmingly, many strains of S. aureus have acquired antibiotic resistance in both nosocomial and
community environments which complicates treatment (71). In fact, S. aureus is said to have
experienced four pandemic waves of antibiotic resistance through history. The first wave started
in the 1940’s, as penicillin resistance emerged shortly after penicillin use began in clinical practice
(71). The second wave similarly started as methicillin resistance emerged in hospitals after the
introduction of methicillin in clinical practice in the 1970’s (71). This was the first isolation of
methicillin-resistant S. aureus, or MRSA, which contained the mobile genetic element, type I
staphylococcal cassette chromosome mec (SCCmec) (71). In the mid 1970’s, the third wave began
as new SCCmec types emerged as the clinical strains MRSA-II and MRSA-III (71). As
vancomycin use increased, vancomycin intermediate S. aureus (VISA) strains emerged as well
(71). These strains exhibited increased resistance to vancomycin than their wildtype counterparts.
The fourth wave began in the mid 90’s, as community acquired strains of MRSA began to emerge
(71). These strains contained SCCmec type IV, which was much smaller and more mobile than
previous strains (71). The USA300 strain emerged around the year 2000 and is the cause of the
pandemic spread of community-acquired MRSA which continues in the United States today (70–
72). In 2002, the first fully vancomycin-resistant S. aureus (VRSA) strain emerged (71).
There is currently no vaccine against S. aureus and increasing emergence of antibiotic-resistant
strains is alarming for individuals that are especially susceptible to invasive S. aureus infection.
Epidemiological data regarding S. aureus infections has been previously reviewed by Tong et. al.
(2015), but here I will summarize some of the key points. Bacteremia is an important clinical
manifestation of S. aureus and occurs when the bacteria invade the host’s bloodstream (73). S.
aureus bacteremia incidence is the largest in the first year of life, and the risk of bacteremia again
increases with age among the elderly (73). Individuals with HIV, injection drug users, and
hemodialysis patients are also at greater risk of acquiring S. aureus bacteremia (73). S. aureus is
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the leading cause of infective endocarditis in industrialized nations (73). Infective endocarditis is
the infection and inflammation of the endocardium, or the inner lining of the heart and valves.
Epidemiologically, the incidence of S. aureus infective endocarditis has increased and the largest
risk factor is contact with health care practitioners (73). Skin and soft tissue infections caused by
S. aureus can range in severity from mild to life-threatening. Community-acquired MRSA has
increased the incidence of S. aureus skin and soft tissue infections, keeping it the leading cause of
this illness worldwide (73). Individuals at risk for these infections include athletes, people
experiencing homelessness, injection drug users, and military workers (73). Therefore, many
subsets of the general population are at risk of contracting serious S. aureus infections. This is also
true for other clinical manifestations caused by S. aureus, such as osteoarticular infections,
prosthetic device infections, pleuropulmonary infections, toxic shock syndrome, epidural
abscesses, meningitis, septic thrombophlebitis, and urinary tract infections (73).
1.2.1 S. aureus virulence factors
S. aureus expresses many virulence factors, which provide it the ability to infect virtually every
tissue in the human body (Table 2). In this section I categorize these virulence factors into four
broad categories: immune-evasion surface factors, MSCRAMMs, extracellular toxins, and
enzymes. There is categorical overlap among some of the examples provided in Table 2, and they
do not cover the entire exhaustive list of S. aureus virulence factors. However, these examples
were chosen to provide a glimpse of the range of virulence factors in S. aureus’ pathogenic arsenal.
Here, I discuss a few virulence factors in more detail. These examples were chosen based on the
relevance of the virulence factors to this study and the topics already introduced in this chapter.
As mentioned in the earlier section, phagocytosis is an important receptor-mediated process of the
innate immune system as it works to eradicate pathogens sometimes marked either by antibodies
or complement. Among its many virulence factors, S. aureus expresses surface factors which allow
it to evade recognition by phagocytes. Like most bacteria, S. aureus contains a polysaccharide
capsule outside its cell envelope, which acts as a primary shield against phagocyte recognition
(74). These capsules are comprised of capsular polysaccharide types 5 and 8 (CP5, CP8), which
each contain repeating units of N-acetyl mannosaminuronic acid, N-acetyl L-fucosamine and Nacetyl D-fucosamine (75). Although the expression of CP5 and CP8 is known to increase in vivo
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survival and the inhibition of phagocytosis, capsule expression is dependent on the location of
infection (76). The extracellular fibrinogen binding protein (Efb) is a protein secreted by S. aureus,
which binds to C3b from the complement system of innate immunity and blocks
opsonophagocytosis (76). Simultaneously, Efb binds fibrinogen, thus surrounding the coccus with
a fibrinogen coat which shields the bacterium from further opsonization (76). These two shielding
mechanisms work together to evade phagocytic uptake and increase S. aureus virulence (76).
Cell-wall anchored proteins (CWAPs) are important for establishing a successful colonization of
host tissue, and for pathogenesis. Collectively, CWAPs enhance the adhesion to and the invasion
of host tissues and cells, as well as the evasion of host immune strategies (77). Near iron transporter
(NEAT) motif proteins are a family of CWAPs which scavenge heme from hemoglobin in ironrestricted environments within the host (77). Iron-regulated surface (Isd) proteins, are a part of the
NEAT motif family, and they transport heme from membranes to the cytosol where the heme can
be oxygenated in order to expel free iron (77). The Isd system is comprised of eleven proteins
translated from five different transcripts on the S. aureus genome (78). Among these, IsdA, IsdB,
IsdC, and IsdH contain at least one NEAT motif (78). NEAT motifs contain 125 amino acids and
are found in proteins that are positioned near putative iron transporters. These motifs each bind
one heme-iron through a tyrosine residue (78). Isd proteins can also allow S. aureus to adhere to
desquamated epithelial cells, resist bactericidal lipids and antimicrobial peptides, invade nonphagocytic cells, accelerate the degradation of C3b, or survive within neutrophils, depending on
which Isd and ligand are involved (77).
S. aureus also secretes many extracellular toxins, including multiple different hemolysins.
Hemolysins are polypeptides that have the ability to lyse blood cells, but each hemolysin that S.
aureus produces has unique properties and roles, some of which are not yet fully understood (79).
α-hemolysins are β-barrel pore-forming toxins, that facilitate the passive transport of molecules
smaller than 2 kDa out of the host cell, thus resulting in necrosis (80, 81). γ-hemolysins are very
similar to α-hemolysins, with the exception that these toxins are comprised of two polypeptides
(82). β-hemolysin is a sphingomyelinase that converts host cell membrane sphingomyelin into
phosphorylcholine and ceramide (83). As a result, β-hemolysin is weakly hemolytic and host cell
death has been proposed to be either due to altered plasma membrane fluidity or through the large
ceramide signaling induced by the toxin (79). δ-hemolysin is a small alpha-helical peptide that has
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three proposed mechanisms of cytolysis: acting as a detergent to solubilize host membranes,
binding and aggregating on host membranes to form pores, and destabilizing the host membrane
by binding to it and altering its curvature (84). The cytolytic activity of hemolysins varies with
regards to which cells are lysed, how they are lysed, and to what degree they are lysed (79). These
variations depend on hemolysin type, species, and cell type (79).

Table 2. Examples of S. aureus virulence factors.

Virulence factor

Examples

Function

Immune-evasive surface factors
Capsules and

Polysaccharide;

Polysaccharide capsule hides cell surface to evade

shields

Efb

opsonisation and recognition by phagocytes. Efb binds
C3b complement and fibrinogen to shield against
phagocytes. (76)

Teichoic acid

Wall; lipid

WTA binds peptidoglycan and contribute to antibiotic
resistance; LTA binds cell membrane and regulates
autolytic wall enzymes (85).

Cell-wall anchored proteins
Sdr family

SdrC/D/E, Bbp

MSCRAMM; SdrC promotes biofilm formation (86);
SdrD binds squamous cells and desomosomal cadherins
(87); SdrE binds complement factor H to evade
complement (88); Bbp binds bone sialoprotein (89).

Clumping factor

ClfA,B

MSCRAMM (90); Clumping factor A binds fibrinogen
and complement regulator factor 1 (91, 92). Clumping
factor B binds fibronectin and cytokeratin 10 (93).
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Protein A

SpA

Binds Fc region of immunoglobulins and Fab region of
B-cell receptors which inhibits opsonophagocytosis and
results in B-cell death (64).

FnBP

FnBPA,B

MSCRAMM (90); FnBPs binds fibronectin and
promotes biofilm formation (94).

Isd

IsdA,B,H

NEAT motif; Binds heme and/or hemoproteins to
remove heme and then transport heme into cell for iron
storage (69).

Extracellular toxins
Hemolysin

α, β, γ, δ

Cause blood cell lysis, allows for nutrient acquisition
(95).

Leukocidin

PVL

Superantigens

SEA,

Destroys leukocytes and causes tissue necrosis (96).
SEB, Pyrogenic toxin superantigens that cause non-specific

TSST-1

T-cell proliferation, by binding MHC II; can cause
emesis or systemic shock (97).

Exfoliative

ETA, ETB

Serine proteases that hydrolyze desmosomal proteins;
causes Staphylococcal scalded skin syndrome (98).

Lipoproteins

SitC, PrsA

Bind TLR2 and signal through MyD88; nutrient
acquisition; some are siderophore binding molecules
for ABC transporters (99).

Phenol-soluble

PSMα/β/γ

modulins
Bacteriocin

Erythrocyte and leukocyte lysis; biofilm development;
simulate inflammation (100).

Staphylococcin

Bactericidal proteins with activity against gram-

412/462/C55,

negative and gram-positive bacteria (101).
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BacR1
Enzymes
Staphylokinase

Sak

Binds plasminogen to disassemble the fibrin net and
invade deep host tissue. Interacts with host HNPs to
prevent defensin-mediated bacteriolysis (102).

Hyaluronidase

Cleave β-1,4 glycosidic bond of host hyaluronic acid,

HysA

allowing S. aureus disseminate through host tissues
(103).
Lipase

Glycerol

ester Inactivate bactericidal lipids, interfere with host

hydrolase

granulocyte function, involved in biofilm formation
(104).

Phospholipases

PIPLC

Catalyzes the cleavage of glycan-phosphatidylinositol
anchored proteins which alters host-cell signaling and
causes cell damage (105).

Proteases

SspA, ScpA

SspA cleaves surface proteins like FnBPs (106, 107).
ScpA degrades fibrinogen, fibronectin, and kininogen;
it also has elastinolytic activity and inactivates host
protease inhibitors (108).

Abbreviations: extracellular fibrinogen binding protein (Efb); microbial surface components
recognizing adhesive matrix molecule (MSCRAMM); serine-aspartate repeat protein (Sdr); bone
sialoprotein-binding protein (Bbp); clumping factor (Clf); finbronectin-binding protein (FnBP);
iron-regulated surface determinants (Isd); Panton-Valentine leucocidin (PVL); Staphylococcal
enterotoxin A/B (SEA/B); toxic shock syndrome toxin 1 (TSST-1); exfoliative toxin A/B
(ETA/B); toll-like receptor 2 (TLR2); SitC is a part of the iron transporter SitABC; peptidyl-prolyl
cis-/trans-isomerase (PrsA); human neutrophil peptide (Hnp); phosphatidylinositol-specific
phospholipase C (PIPLC); Staphylococcal serine protease A (SspA); staphopain A (ScpA).
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1.2.2 Interaction of S. aureus with the macrophage
As shown above, S. aureus utilizes many of its virulence factors to enhance its adhesion, invasion,
and evasion of host immune strategies. Many of these strategies allow S. aureus to evade
phagocytosis. However, the expression of virulence factors is tissue, strain, and host species
dependent. Even when virulence factors are expressed, they may not be adequate to completely
overcome phagocytic recognition and uptake. S. aureus was once considered an extracellular
pathogen, incapable of surviving within host cells. However, many studies have since established
that S. aureus is in fact capable of intracellular survival within phagocytes (109, 110).
Our lab has studied the interaction between S. aureus and human and murine macrophages to
elucidate the mechanisms underlying intracellular survival. Our previous work shows that S.
aureus uses the GraXRS regulatory system to sense and adapt to the acidity encountered in the
macrophage phagolysosome, so that it can survive within this environment (111). Additionally,
our lab has elucidated some aspects on the phagocytosis and trafficking of S. aureus within primary
human macrophages. Through the use of a novel fluorescence-based technique to visualize the
intracellular proliferation of S. aureus in individual macrophages, we show that S. aureus begins
to replicate within the mature phagolysosome approximately 8 hours post-infection (112). Livecell imaging performed by our lab also demonstrates that host cell death occurs before S. aureus
emerges from the macrophage (112). This work shows that during phagocytosis, S. aureus is
trafficked to a mature phagolysosome, and not only survives in the microbicidal environment, but
proliferates as well (112).

1.3

Small colony variants

Small colony variants (SCVs) of S. aureus arise in stressful environments that provide conditions
that are suboptimal for the growth of S. aureus (113). For example, the highly inflammatory
environment of the cystic fibrosis (CF) lung is known to result in the frequent emergence of SCVs
(114). SCVs arise due to spontaneous mutations that occur in the genes involved in the electron
transport chain (113, 115, 116). These mutations disrupt bacterial ATP synthesis through oxidative
phosphorylation, and therefore result in slower growing bacteria (113, 115, 116). Two of the most
common SCVs isolated from clinical samples include the menadione and hemin auxotrophs, which
will be discussed in later sections. These mutations result in the characteristic small colony sizes
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of these SCVs, compared to wildtype colonies (113, 115, 116). Additionally, SCVs are known to
produce much less pigment than their wildtype parental strains (113, 115, 116). While clinical
identification of these strains heavily relies on these phenotypic markers, these strains are capable
of reverting back to the wildtype phenotype, thus making clinical identification and isolation
challenging (113, 115, 116).
SCVs generally produce very little hemolysin when compared to wildtype, making it difficult for
them to access host iron and further limits their growth rate (115, 117). Therefore, an additional
tool for clinical identification of these strains relies on identifying non-hemolytic colonies. SCVs
are also known to be more resistant to certain types of antibiotics than their wildtype counterparts,
which can be explained by a few underlying factors. In part, this is due to a decreased rate of cellwall synthesis, which reduces their susceptibility to antibiotics which target cell-wall biosynthesis,
such as β-lactams (116). Additionally, in the absence of the electron transport chain, the
electrochemical gradients of SCV plasma membranes are disrupted, which results in reduced
uptake of cationic antimicrobial molecules, like aminoglycosides such as gentamicin (116). Small
colony variants are said to persist in chronically infected tissues, longer than their wildtype
counterparts (118). This persistence is often explained by its slow growth, antibiotic resistance,
and other unknown survival advantages (118).
1.3.1 Interactions of SCVs with the macrophage
To investigate why SCVs are correlated with recurrent infections, some have suggested that SCVs
persist within host-cells where they are considered to be protected by antimicrobial compounds
that do not cross the host membrane (116). The nature of the interactions between SCVs and
macrophages is poorly understood. Although host tissues may be effectively cleared of wildtype
S. aureus, SCVs can still be isolated from clinical samples (91, 119–121). To explain this, some
studies have suggested that SCVs persist within the intracellular niches of non-professional
phagocytes, like epithelial and endothelial cells (91, 119–121). These observations are
corroborated by the results of a study which investigates THP-1 human macrophage-like cells
infected with SCV clinical isolates derived from the pulmonary environment of CF patients (122).
This study demonstrates that SCVs persist in the host cell for a much longer period of time than
the wildtype strain (122). Another study investigating THP-1 human macrophage-like cells
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infected with SCVs of S. epidermidis suggests that SCVs of this species do not induce the
macrophage’s oxidative burst as much as the wildtype strain, therefore explaining their
intracellular persistence (123). However, whether this is true for S. aureus has not yet been
investigated. Additionally, whether the SCVs of S. aureus differ from wildtype in how they are
phagocytosed and trafficked through the macrophage remains unknown.
1.3.2 SCVs auxotrophic for menadione
One of the most prevalent S. aureus SCVs isolated from clinical samples is the menadione
auxotroph (124). Wildtype S. aureus utilizes the metabolic shikimate pathway to produce aromatic
amino acids, and an intermediate molecule called chorismate (125, 126). Chorismate is then
converted to menadione, which is eventually isoprenylated to become menaquinone (125, 126).
Menaquinone is the primary electron carrier in the electron transport chain and receives its
electrons either from the NADH oxidase complex or FADH2 (115, 126). There are multiple genes
in the menadione biosynthesis pathway that can be disrupted to result in SCVs that are auxotrophic
for menadione. These genes include menA, menB, menC, menD, menE, menF, and menG (115).
A mutation resulting in an inability to produce menadione, results in the phenotypic characteristics
of SCVs described above, regardless of which gene is disrupted. A transcriptomic analysis of the
menD mutant of S. aureus demonstrates that this mutant has upregulated gene expression of
fermentation and glycolysis proteins when compared to the wildtype (127). This could suggest that
these pathways are used to produce ATP, in the absence of oxidative phosphorylation.
1.3.3 SCVs auxotrophic for hemin
Another prevalent S. aureus SCV isolated from patient samples is the hemin auxotroph. Hemin
biosynthesis enzymes convert glutamate to hemin through a series of steps.

During the

biosynthesis of hemin, SCVs are produced if the following genes are disrupted: hemA, hemB,
hemC, hemD, hemE, hemH, and hemQ (115, 128). The more reduced form of hemin, heme, is also
an electron carrier in the electron transport chain. Heme is a cytochrome component that receives
its electrons from menaquinone in the wildtype strain of S. aureus (115). The same transcriptomic
study mentioned above also analyzed the hemB mutant of S. aureus (115). This mutant similarly
had upregulated fermentation, through the arginine deiminase pathway, when compared to
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wildtype (127). These observations are corroborated by a similar reporter metabolite analysis
(129).

1.4

Cystic fibrosis pulmonary infections

Over the last twenty years, the total prevalence of the Canadian CF population has increased by
approximately 38% (130). CF is an autosomal recessive disorder that leads to chronic and
progressive lung disease (131). This genetic disease is caused by mutations in the cftr gene, which
result in faulty chloride ion channels in epithelial cells (131). In healthy lungs, pulmonary secretory
epithelial cells facilitate the efflux of chloride ions out of the cell, down their electrochemical
gradient. Sodium ions follow this chloride efflux paracellularly, and water leaves the cell due to
the osmotic gradient produced by this salt efflux. In CF lungs, this salt and water efflux can be
severely reduced, and thus results in thick and sticky mucus in the airway space. The mucociliary
clearance of bacteria and other cellular debris is thus hindered and primes the lung for infection
(132). Unfortunately, this environment is often chronically infected with bacteria and inflamed
(131). Such chronic bacterial infections may result in respiratory complications and failure (132).
The Canadian CF Registry Annual Data Report, uses measurements of CF patient lung function to
determine lifetime trends in lung health; from ages six until thirty, most cohorts have shown the
average lung function to decline 1-2% annually (130). Additionally, the most recent report states
that the most common causes of death in the Canadian CF population are related to pulmonary
complications (130). Therefore, to reduce the morbidity and mortality associated with pulmonary
failure, it is important to prevent or treat chronic bacterial infection in this population.
1.4.1 The cystic fibrosis transmembrane conductance regulator
CFTR is a 1480 amino acid long single peptide (133). This glycoprotein is a member of the ATPbinding cassette (ABC) transporter family but is unique because it is the only membrane protein
in this family that acts as an ion channel to facilitate chloride efflux out of the cell (134). The
structure of CFTR is similar to other members in its family, as it contains two transmembrane
domains and two nucleotide binding domains, but is unique because it also contains a regulatory
R domain (135). Each transmembrane region is comprised of six spans of alpha helices, and they
form the translocation pathway (133). The two nucleotide-binding domains exist in the cytoplasm
and are capable of ATP hydrolysis (133). The R domain connects the first nucleotide-binding
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domain to the second transmembrane domain (133). It is hypothesized that the R domain regulates
ion transport by blocking the channel, unless cAMP-dependent protein kinases phosphorylate
serine residues located on the R domain, causing an electrostatic repulsion which opens the channel
(136).
CF can be caused by over 2000 different mutation in cftr. There are currently six classes of cftr
mutation which result in CF (137). Class I mutations arise due to nonsense, frameshift of splicing
events which result in absent or greatly reduced CFTR expression (138). Class II mutations arise
due to incorrect protein processing events such as protein misfolding or premature degradation,
and these events result in a severe reduction of CFTR on the cell surface; the most common CF
mutation ΔF508 is a part of this class (138). Class III mutations lead to the faulty regulation of the
CFTR channel, and result in abnormal gating (138). Class IV mutations impair the ion pore and
result in reduced conductance (139). Class V mutations result in splicing or promotor
abnormalities which alter the abundance of the CFTR protein (140). Class VI mutations reduce
CFTR conformational stability on the plasma membrane or in post-endoplasmic reticulum
compartments (141). The various mutations in CFTR can result in different disease phenotypes,
and can affect ion flux in the lungs, pancreas, and intestine (142). Although CFTR was once
believed to be only expressed on epithelial cells, it is now known to be expressed in other cells of
the body as well, such as neurons and macrophages (143, 144). Thus, cftr mutations have been
hypothesized to affect immune response which is discussed below.
1.4.2 S. aureus and CF
S. aureus is the most prevalent colonizing bacteria isolated from the lungs of Canadian CF patients,
with the most recent statistic reporting isolates from 54% of patients in the past twenty years (130).
S. aureus is capable of infecting most human tissues, with a range of infection severity; severe
infections often occur in children and immunocompromised individuals (145). Infections can be
either nosocomial or community-acquired and alarmingly, antibiotic-resistant strains of S. aureus
are prevalent in both the community and hospital environments (145). Methicillin-resistant S.
aureus (MRSA) has been tracked by the Canadian CF registry since 2003 and has been isolated
from around 6.4% of the Canadian CF population (130).
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In CF patients, colonizations of S. aureus, often localized in the nose, can turn into active infections
in the lower respiratory tract if innate defenses fail (132). In fact, most bacterial infections during
infancy and early childhood in CF patients are caused by S. aureus (146–149). Such infections by
S. aureus can result in multiple detrimental effects in the pulmonary environment (132). During
infancy and early childhood, infections by S. aureus can damage pulmonary epithelial cells,
making them more susceptible to infection and colonization by Pseudomonas aeruginosa (132).
Even the treatment of staphylococcal infection can have lasting effects. For instance, a previous
study has shown that the use of intermittent anti-staphylococcal therapy in CF patients leads to
significantly higher P. aeruginosa acquisition than patients that had not received any therapy at all
(150).
In stressful environments such as the highly inflammatory CF lung, S. aureus colonies can emerge
from host immune cells as small colony variants (SCVs) (151, 152). In fact, a longitudinal study
shows that approximately seventy percent of patients tested positive for pulmonary S. aureus and
SCV colonization (120). Many patients in this study eventually cleared the wildtype strain,
however SCVs were shown to persist for an extended amount of time (120). Despite their
persistence in the CF lung, the nature of their interactions with host immune cells remains highly
uncharacterized (114). Since chronic infections by S. aureus SCVs have been linked with lowered
lung function, it is important to address this gap in knowledge (153).
1.4.3 S. aureus in the context of CF macrophages
Importantly, S. aureus infection contributes to the highly inflammatory environment in the CF
lung, which can be measured by high neutrophil counts and percent IL-8 (147). However,
macrophages are the most common immune cell present and are crucial for mounting innate
immune responses during CF pulmonary infections by S. aureus (24, 154–158). Despite
macrophages being highly recruited to the inflammatory environment of the CF lung, S. aureus
manages to evade macrophage eradication (112, 159–161). Previous studies have produced
evidence to suggest that CFTR-deficient macrophages are inherently deficient in their ability to
eliminate intracellular pathogens (162–164). However, other studies have refuted the mechanisms
suggested to underlie these observations (165, 166). These contrasting observations pose an
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important avenue for further research, as they present a gap in knowledge with regards to the nature
of the interaction between CF relevant intracellular bacteria and CFTR-deficient macrophages.
1.4.4 Proposed mechanism underlying inherent CFTR-dependent macrophage defects: pH
regulation
Multiple studies have suggested that CF macrophages are inherently defective in their ability to
eradicate intracellular bacteria. If this is true, this would render these macrophages even more
susceptible to successful pathogens like S. aureus. A recurring hypothesis regarding the
mechanisms underlying these defects proposes that phagolysosomal pH regulation is CFTRdependent. Di et al. (167) demonstrate that although murine alveolar CFTR-deficient macrophages
retain phagocytic ability, they are defective in killing internalized bacteria. They conclude that
phagolysosomal killing is defective due to the delayed fusion of the alkalinized lysosomes with
nascent phagosomes (167). The same group later published a study which shows that CFTR
inhibitor (CFTRinh-172) treated murine alveolar macrophages have decreased lysosomal
acidification and diminished eradication of P. aeruginosa (164). In corroboration, Zhang et al.
(163) posit that this lysosomal alkalinisation does occur in CFTR-deficient macrophages and
results in the decreased killing of P. aeruginosa. However, they extend this hypothesis by
suggesting that lysosomal alkalinisation perturbs ceramide concentration and therefore perturbs
the microbicidal activation of NADPH dependent ROS release (163).
This recurring hypothesis that suggests that inherent defects in the phagolysosomal killing of
intracellular pathogens by CF macrophages are caused by alkalinized lysosomes has been
contested by multiple studies. Interestingly, one study demonstrates that healthy bone marrow
derived macrophages treated with a CFTR inhibitor present with normal acidification (168). These
results are supported by those of another group that measured the lumenal pH of lysosomes and
phagosomes in cftr-/- murine alveolar macrophages probed with P. aeruginosa; this group found
no change in pH in comparison to control macrophages (169). Additionally, Haggie et al. (165)
found that both murine and isolated human macrophages treated with CFTRinh-172 had unaltered
lysosomal and phagolysosomal pH (165). In discussion, they mention that the results seen by Di
et al. (167) are an artifact of the pH sensitive dye that was used in their experiments, rather than a
depiction of inherent pH irregularities (165).
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Although these studies suggest that lysosomal and phagolysosomal pH remains unaltered when
CFTR is non-functional, they do not discuss whether CFTR plays any role in the acidification of
these compartments. Instead, a study performed by Steinberg et al. (170) suggest that although
CFTR expression and function is required for acidification, cation-ion flux is more prominent in
its effects; this therefore explains why the inhibition of CFTR does not lead to changes in
acidification (170). Thus, whether there is a direct effect of CFTR deficiency on lysosomal and
phagolysosomal acidification in macrophages remains controversial, however appears unlikely.
1.4.5 Proposed mechanism underlying inherent CFTR-dependent macrophage defects:
opsonization
Importantly, there does appear to be increased bacterial survival in CF macrophages in many of
the papers mentioned above, despite the controversy regarding the mechanisms suggested to be
underlying these observations. Some have suggested that these observations are a result of faulty
opsonization. Fick et al. (171) conducted a study on CF patient derived antibodies against P.
aeruginosa in serum and sputum, which demonstrated an inhibitory effect of CF IgG antibodies
on the promotion of phagocytosis. In this study, alveolar macrophages stimulated by CF IgG
demonstrated lower phagocytic rates and lower absolute bacterial uptake when compared to
controls (171). Even more interesting, once CF opsonized bacteria were phagocytosed, the
intracellular killing diminished (171). A few years later, the same group went on to suggest that
the defective opsonophagocytosis they were seeing resulted from fragmented IgG molecules (172).
In relation to this altered opsonization hypothesis, one study has suggested that opsonins in the CF
lung airway surface liquid are degraded by proteases, thereby reducing bacterial clearance (173).
Additionally, it has been suggested by yet another group that CF monocytes require CFTR
expression and function in order to achieve optimal complement-dependent phagocytosis of P.
aeruginosa (174). Although faulty opsonization may be a cause for defective phagocytosis, this
does not explain why CF macrophages present with lowered bacterial killing after successful
phagocytosis.
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1.4.6 Proposed mechanism underlying inherent CFTR-dependent macrophage defects:
phagocytic trafficking
Among the mechanisms suggested to explain this, it has been hypothesized that there are inherent
defects in the trafficking of intracellular bacteria to the phagolysosome. For example, Lamothe et
al. (175) show that infection of murine macrophages with a live relevant CF bacterium,
Burkholderia cenocopecia, induces delayed phagosomal maturation in otherwise healthy
macrophages. In this study, the main method used to measure this delay in maturation was the
measurement of lysosomal-associated membrane protein 1 (LAMP-1) accumulation in
phagosomal vesicles containing B. cenocopecia (175). In a subsequent study, the same group
shows that CFTRinh-172 treated and cftr-/- murine macrophages present with an even greater delay
in phagosomal maturation when infected with this pathogen (168). The results of Simonin-Le
Jeune et al. (176) support these observations, as they demonstrate that CF macrophages have
diminished phagocytic capacity; however, they explain their observations by suggesting that they
are due to both cftr-deficiency and the chronic hyper-inflammatory status of these cells. In
contrast, Del Porto et al. (162) found no differences in the phagocytosis of P. aeruginosa in control
and CF monocyte derived macrophages despite finding an increase in bacterial survival within CF
macrophages. Thus, if there are inherent defects in the CF macrophage’s ability to traffic
intracellular bacteria to the phagolysosome, this may only be specific to certain pathogens.

1.5

Project rationale and hypothesis

With the current ambiguity regarding whether there are inherent defects in the intraphagosomal
killing ability of CFTR-deficient macrophages, it is difficult to form a consensus on the role that
CFTR plays in the macrophage’s microbicidal capacity. From the information available, it appears
likely that if inherent defects do exist, these defects may be present in phagocytic trafficking. The
studies discussed above suggest that this may be the case for CF relevant bacteria, however there
has been no study that has investigated the phagocytic trafficking and bacterial survival within the
phagolysosome of S. aureus in the context of CF macrophages. Whether S. aureus is trafficked to
the phagolysosome and replicates there after a defined time delay is unknown, and my research
will address this gap in knowledge. Additionally, the intracellular fate of SCVs after phagocytosis
by both non-CF and CF macrophages remains to be fully understood. Although SCVs have been
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shown to reside in the phagolysosome during early stages of infection in human macrophage-like
cells, whether they replicate within the phagolysosome is unclear (59). Therefore, given their
importance in the context of CF, my research will investigate this in both non-CF and CF
macrophages.
Due to the increasing prevalence of antibiotic-resistant S. aureus strains, soon alternative
therapeutic measures will be desperately required. Thus, a better understanding of pathogen-host
interactions is vital. If CF patients have increased susceptibility to S. aureus infection due to
inherently defective macrophages that fail to curtail the growth of intracellular bacteria, such a
discovery could illuminate new avenues for anti-staphylococcal strategies and immune
supplements, which could ultimately improve the quality of life of CF patients. Additionally, SCVs
are poorly understood not only in the context of CF macrophages, but also in the context of nonCF macrophages. Due to their intracellular persistence, elucidation of host-pathogen interactions
is not only necessary in illuminating anti-staphylococcal strategies and immune supplements for
CF patients, but any individuals infected with S. aureus.
Based on the prevalence of S. aureus in the CF pulmonary environment, and the high abundance
of macrophages present that fail to curtail chronic infection I hypothesize that CFTR-dependent
macrophage function will be impaired in CF patients, resulting in increased susceptibility to S.
aureus infection.

1.6

Research objectives

To investigate my hypotheses, I have devised two objectives.
1. I will determine whether CFTR-deficient macrophages exhibit inherent defects in their
ability to traffic S. aureus and inhibit its intracellular replication.
2. I will determine if SCVs differ from wild-type S. aureus upon interaction with
macrophages.
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Chapter 2: Materials and Methods
2.1

Reagents

Roswell Park Memorial Institute 1640 medium (RPMI), Tryptic Soy Broth (TSB), and fetal bovine
serum (FBS) were from Wisent Inc. (St. Bruno, QC, Canada). #1 thickness 18 mm diameter round
glass coverslips and paraformaldehyde 16% solution were from Electron Microscopy Science
(Hatfield, PA, USA). Cell Proliferation Dye eFluor-670 was from eBiosciences.
Tetramethylrhodamine-conjugated wheat germ agglutinin (TMR-WGA) was from Molecular
Probes, Thermo Fisher Scientific. CFTRinh-172, Human Recombinant M-CSF, and Lympholyte®poly Cell Separation Media were from Cedarlane. GibcoTM Gentamicin 50 mg/mL, BD BactoTM
Dehydrated Agar, Propidium Iodide, TritonTM X-100 and Tris Base were from Thermo Fisher
Scientific. Menadione Sodium Bisulfite ≥ 95% was from Sigma-Aldrich.

2.2

Bacterial strains and culture conditions

The strains used in this study include S. aureus strain USA300 (plasmid cured), USA300 ΔhemB,
USA300 ΔmenD, and USA300 aroC::ΦNΣ NE1717 (Table 1). I transformed USA300 ΔhemB and
USA300 ΔmenD to carry a constitutive GFP expression vector, pCG44. USA300 (pCG44) was
previously generated by our lab and is a lab stock. Bacterial strains were cultured in tryptic soy
broth (TSB) (Wisent) at 37°C in a shaking incubator, or on TSB agar (1.5% w/v) (TSA) plates.
Strains carrying the pCG44 plasmid were cultured in TSB or on TSA containing 10 µg/mL
chloramphenicol.

Table 3. List of strains and plasmids.
Strain/Plasmid

Description

Source/Reference

Strains
Staphylococcus aureus
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USA300

USA300 LAC; MRSA cured of antibiotic Laboratory stock
resistance plasmids

USA300 Δagr

Strain USA300 with an unmarked deletion Laboratory stock
of the agr operon, which encodes the
accessory gene regulator required for the
expression of many virulence genes.

USA300 ΔhemB

Strain USA300 with an unmarked deletion Laboratory stock
of the hemB gene, which encodes the 5amino- levulinic acid dehydratase required
in heme biosynthesis

USA300 ΔmenD

Strain USA300 with an unmarked deletion Laboratory stock
of the menD gene, which encodes the 2succinyl-6-hydroxy-2,4-cyclohexadiene-1carboxylic acid synthase/2-oxoglutarate
decarboxylase

required

in

menadione

biosynthesis.
USA300 aroC::ΦNΣ

Strain USA300 containing a transposon Laboratory stock
insertion in the aroC gene, which encodes
chorismate

synthase

required

for

chorismate biosynthesis.

NARSA

strain

NE1717

Plasmids
pCG44

Escherichia coli/S. aureus shuttle vector for Gries 2016 (177)
constitutive expression of pHluorin in S.
aureus and used here as a GFP expression
vector. Ampicillin and chloramphenicol
resistant.
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ID:

2.3

Mammalian cell cultures

THP-1 (ATCC® TIB-202TM) cells are human peripheral blood derived monocytes and were from
the American Type Culture Collection (ATCC). THP-1 cells were cultured in suspension in RPMI
1640 (Wisent) which contains L-glutamine, 1.5 g/L sodium bicarbonate, 4.5 g/L glucose, sodium
pyruvate, and is buffered with 25 mM HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic
acid). The RPMI was also supplemented with 10% (v/v) non-inactivated FBS (Wisent).
Subculturing was done every 2-3 days either through the addition of fresh media, or through
replacing a portion of the culture with fresh media to prevent the cell culture from exceeding 10 6
cells/mL. Cells were cultured at 37°C and 5% CO2. To derive macrophage-like cells from THP-1
cells, 100 ng/mL of phorbol 12-myristate 13-acetate (PMA) was added to THP-1’s for 24 h prior
to use.
Primary human M0 macrophages were derived from either non-CF or CF blood donors. First,
peripheral blood mononuclear cells were isolated from donated blood using Lympholyte®-poly
Cell Separation Media (Cedarlane) according to the protocol previously described by the
manufacturer and our lab (112). Next, monocytes were added to glass coverslips and cultured in
RPMI supplemented with 10% (v/v) FBS at 37°C and 5% CO2. For the first five days of incubation,
the media contained 10 ng/mL human recombinant macrophage colony-stimulating factor (MCSF), penicillin, and streptomycin. On the 5th day, cells were washed thoroughly with 1X
phosphate-buffered saline (PBS), and fresh media containing only RPMI, FBS, and M-CSF was
added for 2 additional days. The purpose of the wash and removal of antibiotic was to minimize
internalization of antibiotic through the macrophage’s fluid-phase uptake. Macrophages were used
between days 7 and 10.
RAW 264.7 cells (RAWs) (ATCC® TIB-71™) are an adherent murine macrophage cell-line
purchased from the ATCC. RAWs were cultured in either a T25 or T75 (Thermo Fisher Scientific)
plastic flask in RPMI supplemented with 5% (v/v) FBS. Cultures were passaged by scraping and
diluting in fresh media, once every 2-3 days at a subculture ratio of 1:3. Cells were passaged up to
a maximum of 6 weeks, before seeding a new plate from liquid nitrogen stored cultures.
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2.4

CFTRinh-172 treatment of macrophages

In some experiments in this project, THP-1 macrophage-like cells and primary human M0
macrophages were treated with a CFTR inhibitor. This inhibitor is known to induce a reversible
and concentration-dependent inhibition of CFTR when applied to mammalian cells at 5 µM (178).
This concentration optimizes selective and maximal inhibition of the CFTR channel’s Clconductance. In experiments that required CFTR inhibition, the inhibitor was added to the
macrophage tissue culture medium for 1 h prior to the start of the experiment and was kept on
throughout the duration of the experiment.

2.5

Gentamicin protection assays

Gentamicin protection assays were performed in accordance to protocols described by our lab
(112). Bacterial overnight cultures were grown in TSB, pelleted and washed with saline, then
diluted in RPMI to obtain the correct cell-density required for either an MOI of either 10 or 30,
depending on the experiment. Macrophages were seeded in 12-well plate wells prior to the
experiment, in the tissue culture media specific to the macrophage type. Macrophages were
infected by adding 1 mL of the inoculated RPMI, then centrifuging the plate for 2 min at 277 x g
to synchronize phagocytosis, and incubating the plate for 30 min at 37°C. After this incubation
period, the media was removed, and 1 mL of RPMI containing 100 µg/mL of gentamicin was
added to each well. The macrophages were then incubated for 1 h at 37°C, in order to allow for
effective killing of extracellular bacteria by the antibiotic.
After this incubation period, the media was removed, and each well was washed once with 2 mL
of 1X PBS to remove traces of antibiotic and dead bacteria within the well. At this timepoint, 1.5
hpi, designated wells were treated with 500 µL of 0.1% Triton X-100 for 5 min to lyse
macrophages. All other wells would receive fresh RPMI, either with or without FBS dependent on
the experiment in question and would be incubated at 37°C until the later designated timepoint. At
this timepoint, macrophage culture media would be isolated and pelleted to obtain any live
extracellular bacteria. The macrophages would then be similarly treated with Triton X-100. In
order to enumerate intracellular bacteria, macrophage lysates were serially diluted in saline. 10 µL
of each dilution was drop-plated on TSA and incubated at 37°C overnight. The next day, colony-
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forming units per mL (CFU/mL) would be calculated from the observed colony forming units on
the TSA.

2.6

Preparing electrocompetent USA300 ΔhemB and USA300 ΔmenD

These strains were grown overnight in TSB. Overnights were then used to inoculate 400 mL TSB
at a starting OD600 of 0.01, and the cultures were incubated at 37°C in a shaking incubator. OD600
measurements were periodically taken until the cultures each reached a measurement of 0.3. The
cultures were then placed on ice for 10 min. The cells were pelleted for 10 min at 9000 g and 4°C.
The pellets were resuspended in 40 mL of 0.5 M sterile sucrose at 4°C. Cells were pelleted again
for 10 min, min at 9000 g and 4°C. The pellets were resuspended in 5 mL of 0.5 M sterile sucrose
at 4°C, then incubated on ice for 20 min. Cells were pelleted again for 10 min, min at 9000 g and
4°C. The pellets were resuspended in 1.5 mL of 0.5 M sterile sucrose at 4°C, then aliquoted into
pre-chilled microcentrifuge tubes (Axygen, Thermo Fisher Scientific), and stored at -80°C.

2.7

Plasmid prep of pCG44

A plasmid preparation was performed on a laboratory stock of USA300 (pCG44), to isolate the
plasmid. This preparation was done using the E.Z.N.A.® Plasmid Mini Kit I (Omega), following
manufacturer protocols. Isolated plasmid concentration fell between the range of 50-1000 ng/µL.

2.8

Transformation of pCG44 into USA300 ΔhemB and USA300 ΔmenD

Competent cells were thawed on ice. 5 µL of the pCG44 plasmid were added to the competent
cells, the cells were mixed by gentle flicking, and then incubated on ice for 30 min. Cells were
then pipetted into a chilled cuvette and were then electroporated at 200 ohms for around 5 ms.
Cells were recovered with 940 μL TSB containing 1 μg/mL chloramphenicol. Cells were
resuscitated at 37°C for 60 min, then spread plated on TSA containing 10 μg/mL chloramphenicol
that was incubated at 37°C for 24 h. Colonies were picked, grown in overnight TSB cultures, and
frozen down into glycerol stocks stored at -80°C. To ensure that the strains were indeed
transformed, a fluorescence imaging plate reader was used for confirmation.
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2.9

eFluorTM-670-based proliferation assays

The wildtype and mutant strains of USA300 carrying the pCG44 plasmid were all used in these
assays, following protocols published by our lab (179). Overnight cultures of the strains were
grown in TSB. 1 mL of each overnight was pelleted at 21 000 g for 2 min, washed with saline, and
pelleted again. The pellet was resuspended in 0.9% (w/v) saline containing 5 µg/mL eBioscience™
Cell Proliferation Dye eFluor™-670 for 5 minutes, then pelleted again. The pellet was resuspended
in TSB to quench the dye for 5 min, then pelleted again. The pellet was resuspended in RPMI, and
macrophage infections were performed as described above. Macrophages were seeded onto 18 mm
glass coverslips in 12-well plates. Instead of lysing gentamicin-treated macrophages at 1.5 hpi,
and various later timepoints, the macrophages were fixed onto the coverslips using 4% (v/v) PFA
(16% PFA diluted in 1x PBS) for 20 min. Prior to fixation, 1 µg/mL of TMR-WGA diluted in 1X
PBS was added to the wells for 2 min to stain the macrophages. Coverslips were then imaged by
widefield fluorescence microscopy

2.10 Fluorescence Microscopy
A Leica DMi6000B inverted microscope was used to perform all widefield fluorescence and
differential inference contrast (DIC) microscopy. The photometrics Evolve 512 Delta EM-CCD
camera was used to obtain images. All images used for this study were taken using the 100x (NA
1.4) oil immersion PL-Apo objective and the Leica 100W Hg high-pressure light source. In the
analysis of eFluor-670-based proliferation assays, the EM gain, excitation intensity, and
exposure time parameters for the far-red visualization of eFluor-670 positive Staphylococci were
always determined based on the 1.5 h timepoint when all Staphylococci were eFluor-670
positive. These parameters were chosen for each experiment, to obtain the optimal fluorescence
parameters and avoid oversaturation. Later timepoints were therefore visualized using the same
parameters, which allowed for a reliable comparison between the timepoints and therefore, a
consistent interpretation of the intracellular replication visualized. Images were edited and
processed using Fiji (Fiji Is Just ImageJ) software (180).
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2.11 Creating RPMI + depleted 5% FBS media
A flask containing 30 mL of RPMI was supplemented with 5% FBS. This media was inoculated
with USA300 ΔmenD at a starting OD600 of 0.001. This culture was incubated in a shaking aerobic
incubator for 24 h at 37°C. The culture was then filter-sterilized twice using a 0.22 µm filter. This
media was created and used for multiple different experiments, where it would then be inoculated
once again by fresh overnight culture, according to the experimental protocol.

2.12 UV-vis absorbance spectroscopy measurements of Soret peak
In the experiment conducted to obtain the representative multigraph data in Fig. 13, multiple
scanning UV-vis absorbance spectroscopy readings were performed for various treatment groups
to indicate the presence or absence of the Soret peak (indicated on graph). As a positive control
WT USA300 was used and the spectral scan detected the presence of a Soret peak. To account for
the approximate ten-fold difference between culture OD’s of the WT and mutant, one treatment
group was normalized for OD600 before starting the culture (Fig. 13C), while another group was
not normalized (Fig. 13E). A Triton-induced hemolysis positive control was also used to
chemically lyse RBCs and yield the same Soret peak (Fig. 13D). Each labeled treatment group on
the graph corresponds with the following treatment conditions:
A. 300 μL of USA300 ΔmenD overnight culture was added to 150 μL red blood cells, and
TSB was added to achieve 3 mL total in an in vitro 13 mL polypropylene snap-cap tube
(Sarstedt).
B. 30 μL of USA300 Δagr overnight culture was added to 150 μL red blood cells, and
TSB was added to achieve 3 mL total in an in vitro 13 mL polypropylene snap-cap tube
(Sarstedt).
C. 30 μL of USA300 overnight culture was added to 150 μL red blood cells, and TSB was
added to achieve 3 mL total in an in vitro 13 mL polypropylene snap-cap tube
(Sarstedt).
D. 300 μL of 0.1% Triton X100 was added to 150 μL red blood cells, and TSB was added
to achieve 3 mL total in an in vitro 13 mL polypropylene snap-cap tube (Sarstedt).
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E. 300 μL of USA300 overnight culture was added to 150 μL red blood cells, and TSB
was added to achieve 3 mL total in an in vitro 13 mL polypropylene snap-cap tube
(Sarstedt).
Culture tubes were left on a table-top at room temperature. At 20 h post-inoculation, samples were
obtained from the middle of each culture tube, without disturbing any RBC fragments which had
been deposited at the bottom of the tube. These samples were then analyzed by UV-Vis
spectroscopy. Experiments were performed 3 times, with three biological replicates for each
treatment group.

2.13 Gentamicin protection assay mock infections
Each well in a 12-well plate was filled with 1 mL of either RPMI supplemented with 5% FBS, or
RPMI alone (serum free, SF). Plates were incubated in a static aerobic incubator for 12 h at 37°C.
At 12 h, the media was removed and discarded. Designated wells were washed with 2 mL of 1X
PBS or were left unwashed. 1 mL of RPMI alone was added to each well, either inoculated with
WT USA300 or USA300 ΔmenD at a starting OD600 which would resemble an MOI of 30 if 500,
000 macrophages were present in each well. In designated wells, 0.8 µg/mL menadione was added
in to serve as a positive growth control for USA300 ΔmenD. Plates were incubated in a static
aerobic incubator for 24 h at 37°C. Endpoint OD600 readings were then measured for each well.
Experiments were performed at least 3 times and each experiment contained 3 biological
replicates.

2.14 Bacterial growth experiments
All in vitro growth experiments were performed in 13 mL polypropylene snap-cap tubes (Sarstedt),
containing a maximum culture volume of 3 mL. Cultures were composed of various media and
inocula, as described in each individual results section. Unless otherwise stated, cultures were
incubated in a shaking aerobic incubator for 24 h at 37°C. In experiments where acidity of the
culture was altered, a 0.1 M tris-maleate buffer was used to maintain the set pH throughout the
experiment.

38

2.15 Stimulating RAW 264.7 macrophages with heat-killed S. aureus
In Eppendorf tubes, 1 mL of overnight TSB culture of USA300 ΔmenD was pelleted, resuspended
in 1 mL of saline, pelleted, then resuspended in 1 mL of RPMI. The OD600 of these cultures were
measured. The cultures were then heated on a 90°C heat block for 40 min to kill the bacteria. Either
a T-25 or T-75 flask was seeded with RAWs, to achieve a confluency of ~90%. The tissue culture
media was removed, and the macrophages were washed with the same volume of 1X PBS. Based
on the starting OD600, a calculated volume of heat-killed culture was added to the fresh RPMI to
mimic an MOI of 30. This culture was then added to the washed macrophages, and flasks were
incubated in a static aerobic incubator for 24 h at 37°C.

2.16 Ethics Statement
Blood was obtained with permission from healthy adult volunteers, in compliance with protocol
109059 approved by the Office of Research Ethics at the University of Western Ontario. Blood
was obtained with permission from CF patients attending the London Health Science Centre Cystic
Fibrosis Clinic at Victoria Hospital in London, Ontario in compliance with protocol R-17-255
approved by the Office of Research Ethics at the University of Western Ontario.

2.17 Statistical analyses and software
Graph production and statistical analyses was performed using the GraphPad Prism software
(GraphPad Software, La Jolla, CA). The data are demonstrated as mean ± SD. Where possible, a
D’Agostino and Pearson normality test determined if the data was normal. If the data were normal,
an unpaired two-tailed t-test was used to determine the difference in two means and an ordinary
one-way nonparametric ANOVA test and Tukey’s post-hoc multiple comparison of the means
were performed to determine the difference between multiple means. If the data were not normal,
an unpaired Mann-Whitney nonparametric two-tailed test was used to determine the difference in
two means and a Kruskal-Wallis nonparametric test and Dunn’s post-hoc multiple comparison of
the means were performed to determine the difference between multiple means. *P<0.05,
**P<0.01, ***P<0.001, ****P<0.0001.
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Chapter 3: Results
3.1

Investigating the role of CFTR in macrophage defense against S. aureus

USA300
3.1.1. THP-1 derived macrophages contain replicating USA300 irrespective of CFTR
inhibitor treatment.
To investigate the role of CFTR in the macrophage’s defense against S. aureus, a cell-based model
of infection was employed using three different types of macrophages that were cultured in vitro.
In this section, the monocyte cell line THP-1 derived from human peripheral blood, was
differentiated into macrophages using phorbol 12-myristate 13-acetate (PMA). This cell line was
chosen because of its use in previous CF studies since these cells express CFTR on their plasma
membrane (181–183). To perturb CFTR function, differentiated THP-1 cells were treated with a
reversible voltage-gate independent CFTR inhibitor (CFTRinh-172) which was maintained
throughout the course of the infection. This inhibitor has been used in previous studies to
investigate the role of CFTR in macrophage immune function (164, 168) and the concentration (5
µM) used herein is based on a previously optimized protocol (178). Here methicillin-resistant S.
aureus strain USA300 was used for THP-1 macrophage infection to determine how loss of CFTRfunction impacts the ability of S. aureus to survive and replicate intracellularly.
Gentamicin protection assays were performed using differentiated THP-1 macrophages that were
treated with and without the CFTR inhibitor and immediately after gentamicin treatment, at 1.5
hours post-infection, macrophages containing phagocytosed bacteria were lysed and plated to
determine the number of intracellular bacteria (Fig. 3A). The same was done at 20 hours postinfection (Fig. 3A). At 1.5 and 20 h post-infection there was no significant difference between the
number of S. aureus recovered from macrophages irrespective of CFTR inhibitor treatment (Fig.
3A). Analysis of the bacterial burden at 1.5 h post-infection as compared to 20 h post-infection
revealed that there is an increase in the observed CFU/mL for both treatment groups.
However, because phagocytosis is a heterogeneous process and the absolute number of bacteria
internalized by macrophages can vary between experiments, the fold-change in CFU/ mL was
measured. To do this the bacterial burden at 20 h post-infection was normalized to the bacterial
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burden at 1.5 h post-infection for a given biological replicate; this was done to better detect
replication and allow for direct comparisons between individual experiments (Fig. 3B). Both
treatment groups exhibit a mean fold-change that is greater than 1 indicating intracellular bacterial
replication is occurring within these populations of macrophages (Fig. 3B). Control infections
yield a mean fold change in CFU/mL of 8.8 whereas CFTR inhibitor treated macrophage-like cells
yielded a mean fold change of 6.1 which is modestly, yet nonetheless statistically significantly,
reduced relative to control (Fig. 3B). Therefore, THP-1 derived macrophage-like cells contain
replicating USA300 irrespective of CFTR inhibitor treatment, and replication was significantly
reduced in cells treated with CFTR inhibitor.

A

B

Figure 3. THP-1 derived macrophages contain replicating USA300 irrespective of CFTR
inhibitor treatment. THP-1 macrophages in the absence or presence of 5 µM CFTR inhibitor
(CFTRinh-172), were infected with S. aureus USA300 at a MOI of 10 and gentamicin protection
assays were performed. A) Enumerated CFU/mL were obtained from control and CFTR inhibitor
treated cells at 1.5 and 20 hpi. The data represent the mean CFU/mL ± SD. A Kruskal-Wallis
nonparametric test and Dunn’s post-hoc multiple comparison of the means was performed to
determine significance between the CFU/mL obtained for S. aureus USA300 at the earlier or later
timepoints, in the presence or absence of the CFTR inhibitor. In B) the fold-change of CFU/mL
for each biological replicate was calculated for each treatment group, between the two timepoints.
Each data point represents the fold-change for each biological replicate of the bacterial strain
infecting a unique population of macrophages, and experiments were performed at least 3 times
per treatment group. The dotted line indicates 1 on the y axis which represents no replication.
Statistical significance was determined by an unpaired Mann-Whitney nonparametric two-tailed
test to compare infected macrophages treated with and without the CFTR inhibitor. *P<0.05.
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3.1.2 CFTRinh-172 treated primary human M-CSF-derived macrophages contain replicating
USA300 and are more permissive to bacterial growth.
Here, primary human macrophages derived from peripheral blood monocytes obtained from
healthy donors were used to investigate the role of CFTR function during intracellular S. aureus
infection. Macrophages were differentiated using M-CSF according to the protocol described in
the methods and macrophages were then either treated with and without the CFTR inhibitor. This
model was used because unlike THP-1 macrophage-like cells, primary macrophages are not
immortalized therefore they better represent macrophages that might be encountered during
infection (184).
Primary human macrophages were infected as described above and gentamicin protection assays
were again performed where the intracellular bacterial burden was determined at 1.5 and 20 h postinfection. The bacterial burden did not differ between these timepoints for infected control
macrophages (Fig. 4A). However, the bacterial burden recovered from CFTR inhibitor treated
macrophages significantly increased between these timepoints (Fig. 4A). The fold-change of the
bacterial burden between the earlier and later timepoints was determined (Fig. 4B). Control
infections yield a mean fold change in CFU/mL of 1.9 whereas CFTR inhibitor treated
macrophages yielded a mean fold change of 4.5 which is modestly increased relative to the control
(Fig. 4B). Intracellular growth was indicated by a positive calculated mean fold-change. Both
treatment groups demonstrate a positive fold-change between the two timepoints, thus suggesting
that intracellular replication is occurring in these populations of macrophages (Fig 4B). Therefore,
irrespective of CFTRinh-172 treatment primary human M-CSF-derived macrophages contain
replicating S. aureus USA300. However, CFTR inhibition renders infected cells more permissive
to bacterial growth.
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Figure 4. CFTRinh-172 treated primary human M-CSF-derived macrophages contain
replicating USA300 and are more permissive to bacterial growth. Gentamicin protection assay
was performed on S. aureus infected primary human M-CSF derived macrophages in the absence
and presence of 5 µM CFTR inhibitor (CFTRinh-172). Macrophages were infected with S aureus
USA300 at an MOI of 10. A) The bacterial burden was determined for infected control and CFTR
inhibitor treated macrophages at 1.5 and 20 hpi. The data represent the mean CFU/mL ± SD.
Statistical significance was determined by an ordinary one-way nonparametric ANOVA test and
Tukey’s test of multiple comparisons, * P<0.05. B) A fold-change of CFU/mL for each biological
replicate was calculated for each treatment group, between the two timepoints. Each data point
represents the fold-change for each biological replicate of the bacterial strain infecting a unique
population of macrophages, and experiments were performed at least 3 times per treatment group.
The dotted line indicates 1 on the y axis which represents no replication. An unpaired t-test
determined that there was no significant difference in intracellular growth between control and
CFTR inhibitor treated macrophages.

3.1.3 Primary M-CSF differentiated macrophages derived from CF patients contain
replicating S. aureus USA300.
In this section, primary macrophages derived from the peripheral blood monocytes isolated from
CF patients attending the London Health Science Centre Cystic Fibrosis Clinic at Victoria Hospital
in London, Ontario were used for S. aureus infection. All ethical protocols were approved and
followed during the collection and use of donor blood. As described above, gentamicin protection
assays were performed to determine if control and CF macrophages would differ in bacterial
burden when infected with USA300 between 1.5 and 12 hpi. Between the 1.5 and 12 h timepoints
post-infection, the bacterial burden recovered from control macrophage lysates (derived from non43

CF patients) do not significantly differ (Fig. 5A). However, the bacterial burden recovered from
CF patient macrophages do significantly increase between these timepoints (Fig. 5A). I determined
the fold-change of bacterial burden between 12 hpi and 1.5 hpi (Fig. 5B). Control infections yield
a mean fold change in CFU/mL of 9.1 whereas CF macrophages yielded a mean fold change of
12.2, and there are no statistically significant differences between the groups (Fig. 5B).
Intracellular growth was indicated by a positive calculated mean fold-change. Both treatment
groups demonstrate a positive fold-change between the two timepoints (Fig 5B). Thus, this data
shows that USA300 replicates intracellularly in CF patient derived primary M0 macrophages.
Gentamicin protection assays reveal that in the population of macrophages there is an increased
bacterial burden with time. However, to obtain a better understanding of the intracellular events I
performed fluorescence-based proliferation assay to allow for single cell analysis of bacterial
replication. This was achieved by performing eFluor-670-based proliferation assays on
macrophages infected with eFluor-670 stained GFP-expressing USA300 following the protocol
described in the methods. Bacteria that have replicated intracellularly are indicated by the presence
of GFP-expressing S. aureus that are proliferation dye negative within macrophages (Fig. 5C).
These results demonstrate that a subset of CF patient derived primary M0 macrophages contain
replicating intracellular S. aureus.
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Figure 5. Primary M-CSF differentiated macrophages derived from CF patients contain
replicating S. aureus USA300. Gentamicin protection assays were performed using non-CF
(control) and CF (patient) primary human M-CSF-derived macrophages were infected with S.
aureus USA300 at a MOI of 10 and the bacterial burden was determined. A) The bacterial burden
was determined for infected control and patient macrophages at 1.5 and 12 hpi. The data represents
the mean CFU/mL ± SD. A Kruskal-Wallis nonparametric test followed by a Dunn’s post-hoc
multiple comparison of the means was performed to determine statistical significance.
***P<0.001. B) A fold-change of CFU/mL for each biological replicate was calculated for each
treatment group, between the two timepoints. Each data point represents the fold-change for each
biological replicate of the bacterial strain infecting a unique population of macrophages, and
experiments were performed at least 3 times per treatment group. The dotted line indicates 1 on
the y axis which represents no replication. An unpaired Mann-Whitney nonparametric two-tailed
test was performed and determined that there was no significant difference in intracellular growth
between control and CF patient macrophages. C) Representative widefield microscopy images
demonstrate CF patient macrophages infected with USA300 following eFluor-670-based
proliferation assay protocols viewed in DIC (first panel) and multiple fluorescence channels, at 1.5
and 12 hpi. WGA stained macrophage plasma membranes are shown in red, eFluorTM-670 positive
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S. aureus (in blue), and GFP-expressing S. aureus (in green). White arrows indicate clusters of S.
aureus that GFP-positive yet are proliferation dye negative, indicating bacterial replication. Images
are representative of at least three independent experiments, scale bars equal 10 μm.

3.2

Investigating the role of CFTR in macrophage defense against USA300

ΔhemB
3.2.1 THP-1 derived macrophages contain replicating S. aureus USA300 ΔhemB
irrespective of CFTR inhibitor treatment.
To investigate my second objective, which is to determine whether the intracellular fate of S.
aureus SCVs differs from wildtype bacteria within macrophages, I employed cell-based infections
as described above. To characterize the fate of SCV bacteria inside macrophages I used mutant
strains of S. aureus engineered in the Heinrichs lab, that carry gene deletions of either hemB
(USA300 hemB) or menD (USA300 menD). Strains carrying these deletions were created
because disruption of these genes is known to cause SCV formation (113, 115, 116). Moreover,
because clinical SCV isolates continuously revert back to the wildtype phenotype during passage
we wanted stable SCV mutants that could not revert (113, 115, 116). In this section, I discuss the
results of gentamicin protection assays that were performed using PMA differentiated THP-1
macrophage-like cells infected with the SCV hemin auxotroph USA300 ΔhemB and wild-type S.
aureus USA300 as a control.
To test the role of CFTR in the context of SCV infection, differentiated THP-1 cells were treated
with and without the CFTR inhibitor. At 1.5 and 20 hpi, macrophages containing phagocytosed
bacteria were lysed and plated to determine the intracellular bacterial burden (Fig. 6A). This
analysis revealed that in the presence or absence of the CFTR inhibitor neither strain exhibited a
statistically significant difference in intracellular bacterial burden between the two timepoints (Fig.
6A).
The fold-change of the bacterial burden between the earlier and later timepoints was determined
(Fig. 6B). Wildtype infections yield a mean fold change in CFU/mL of 8.8 in the absence of the
CFTR inhibitor, and 6.1 in the presence of the inhibitor (Fig. 6B). SCV infections yield a mean
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fold change in CFU/mL of 9.0 in the absence of the CFTR inhibitor, and 7.4 in the presence of the
inhibitor (Fig. 6B). Intracellular growth was indicated by a positive calculated mean fold-change.
All treatment groups demonstrate a positive fold-change between the two timepoints (Fig 6B).
However, there was no statistically significant difference between any of the treatment groups
(Fig. 6B). Therefore, THP-1 derived macrophages contain replicating S. aureus USA300 ΔhemB
irrespective of CFTR inhibition.
A

B

Figure 6. THP-1 derived macrophages contain replicating S. aureus USA300 ΔhemB
irrespective of CFTR inhibitor treatment. THP-1 macrophages in the absence or presence of
CFTRinh-172 treatment were infected with either wildtype USA300 (WT) or USA300 ΔhemB at
an MOI of 10, and the gentamicin protection assay protocol was followed as described in the
methods. A) The data represents the mean CFU/mL ± SD. A Kruskal-Wallis nonparametric test
and Dunn’s post-hoc multiple comparison of the means was performed and determined no
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significant differences among the means. B) The fold-change in CFU/mL for each biological
replicate was calculated for each treatment group where bacterial counts at 20 h post-infection
were normalized by the bacterial burden at 1.5 h post-infection. The dotted line indicates 1 on the
y axis which represents no replication. Each point represents a biological replicate of the bacterial
strain in a unique population of macrophages. An unpaired Mann-Whitney nonparametric twotailed test was performed and determined no significant differences among the means. Experiments
were performed more than 3 times per treatment group.

3.2.2 Primary human M-CSF-derived macrophages contain replicating USA300 ΔhemB
irrespective of CFTR inhibitor treatment.
Gentamicin protection assays were performed as described above, but here primary human MCSF-derived macrophages were infected with USA300 ΔhemB. To investigate the role of CFTR
in these macrophages infected with this mutant, the macrophages were treated with the CFTR
inhibitor as described above. Wildtype USA300 was used as a bacterial control in both macrophage
treatment groups. At 1.5 and 20 hpi, macrophages containing phagocytosed bacteria were lysed
and plated to determine the intracellular bacterial burden (Fig. 7A). This analysis revealed that in
the absence of the CFTR inhibitor, USA300 ΔhemB. exhibited a modest increase in intracellular
bacterial burden between the two timepoints (Fig. 7A).
I determined the mean fold-change of bacterial burden between 20 hpi and 1.5 hpi (Fig. 7B).
Wildtype infections yield a mean fold change in CFU/mL of 1.9 in the absence of the CFTR
inhibitor, and 4.5 in the presence of the inhibitor (Fig. 7B). SCV infections yield a mean fold
change in CFU/mL of 6.4 in the absence of the CFTR inhibitor, and 9.0 in the presence of the
inhibitor (Fig. 7B). Intracellular growth was indicated by a positive calculated mean fold-change.
All treatment groups demonstrate a positive fold-change between the two timepoints (Fig 7B).
However, there was no statistically significant difference between any of the treatment groups
(Fig. 7B). Therefore, this data shows that primary human M-CSF-derived macrophages contain
replicating USA300 ΔhemB irrespective of CFTR inhibitor treatment.
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Figure 7. Primary human M-CSF-derived macrophages contain replicating USA300 ΔhemB
irrespective of CFTR inhibitor treatment. Primary human M-CSF derived macrophages were
infected with either wildtype USA300 (WT) or USA300 ΔhemB at an MOI of 10 and gentamicin
protection assays were performed. A) The data represent the mean CFU/mL ± SD. Statistical
significance was determined by an ordinary ANOVA test with multiple comparisons, ** P<0.01.
B) The fold-change in CFU/mL for each biological replicate was calculated for each treatment
group where bacterial counts at 20 h post-infection were normalized by the bacterial burden at 1.5
h post-infection. The dotted line indicates 1 on the y axis which represents no replication. Each
point represents a biological replicate of the bacterial strain in a unique population of macrophages.
An unpaired Mann-Whitney nonparametric two-tailed test was performed and determined that
there was no significant difference in intracellular growth between control and inhibitor treated
macrophages infected with either strain. Experiments were performed more than 3 times per
treatment group.
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3.2.3 Primary M-CSF differentiated macrophages derived from CF patients contain
replicating S. aureus USA300 ΔhemB.
Gentamicin protection assays were performed on CF patient derived primary M0 macrophages,
infected with either wildtype USA300 or USA300 ΔhemB. As a control, M0 macrophages derived
from healthy individuals were also infected with either strain. At 1.5 and 12 hpi, macrophages
containing phagocytosed bacteria were lysed and plated to determine the intracellular bacterial
burden (Fig. 8A). Between the 1.5 and 12 h timepoints post-infection, the bacterial burden
recovered from control macrophage lysates do not significantly differ (Fig. 8A). However, the
bacterial burden recovered from CF patient macrophages do significantly increase between these
timepoints (Fig. 8A). I determined the fold-change where the bacterial burden counts at 12 hpi
were normalized to 1.5 hpi (Fig. 8B). Control infections yield a mean fold change in CFU/mL of
3.6 whereas CF macrophages yielded a mean fold change of 7.4, and there is no statistically
significant difference between the groups (Fig. 8B). Intracellular growth was indicated by a
positive calculated mean fold-change. Both treatment groups demonstrate a positive fold-change
between the two timepoints (Fig 8B). Thus, this data shows that USA300 ΔhemB replicates
intracellularly in CF patient derived primary M0 macrophages.
Gentamicin protection assays reveal that in the population of macrophages there is an increased
bacterial burden with time. However, to obtain a better understanding of the intracellular events I
performed fluorescence-based proliferation assay to allow for single cell analysis of bacterial
replication. Therefore, in order to do this, I performed eFluor-670-based proliferation assays on
macrophages infected with eFluorTM-670 stained GFP-expressing USA300 ΔhemB following the
protocol described in the methods. Bacteria that have replicated intracellularly are indicated by the
presence of GFP-expressing S. aureus that are proliferation dye negative within macrophages (Fig.
8C).
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Figure 8. Primary M-CSF differentiated macrophages derived from CF patients contain
replicating S. aureus USA300 ΔhemB. CF patient and non-CF (Control) primary human M0
macrophages were infected with USA300 ΔhemB at an MOI of 10, and the gentamicin protection
assay was performed. A) Enumerated CFU/mL were obtained from control and CF macrophages
at 1.5 and 12 hpi. The data represents the mean CFU/mL ± SD. A Kruskal-Wallis nonparametric
test and Dunn’s post-hoc multiple comparison of the means were performed and determined
statistical significance, *P<0.05. B) A fold-change of CFU/mL for each biological replicate was
calculated for each treatment group, between the two timepoints. Each data point represents a
unique biological replicate of the bacterial strain infecting a unique population of macrophages,
and experiments were performed at least 3 times per treatment group. The dotted line indicates 1
on the y axis which represents no replication. An unpaired t-test determined that there was similarly
no significant difference in intracellular growth between control and CF patient macrophages. C)
Representative widefield microscopy images demonstrate CF patient macrophages infected with
USA300 ΔhemB following eFluor-670-based proliferation assay protocols viewed in DIC (first
panel) and multiple fluorescence channels, at 1.5 and 12 hpi. WGA stained macrophage plasma
membranes are shown in red, eFluorTM-670 positive S. aureus (in blue), and GFP-expressing S.
aureus (in green). White arrows indicate clusters of S. aureus that GFP-positive yet are
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proliferation dye negative, indicating bacterial replication. Images are representative of at least
three independent experiments, scale bars equal 10 μm.

3.3

Investigating the role of CFTR in macrophage defense against USA300

ΔmenD
3.3.1 THP-1 derived macrophages do not contain replicating S. aureus USA300 ΔmenD
irrespective of CFTR inhibitor treatment.
To continue investigating my second objective and to determine whether all SCVs behave
similarly inside macrophages, I repeated the same experiments as the last section with the
menadione auxotroph SCV, USA300 ΔmenD. As described above, THP-1 macrophages were
treated with and without the CFTR inhibitor. At 1.5 and 20 hpi, macrophages containing
phagocytosed bacteria were lysed and plated to determine the intracellular bacterial burden (Fig.
9A). This analysis revealed that in the presence or absence of the CFTR inhibitor neither strain
exhibited a statistically significant difference in intracellular bacterial burden between the two
timepoints (Fig. 9A). I determined the fold-change where the bacterial burden counts at 20 hpi
were normalized to 1.5 hpi (Fig. 9B). Wildtype infections yield a mean fold change in CFU/mL of
8.7 in the absence of the CFTR inhibitor and 5.2 in the presence of the inhibitor, demonstrating a
statistically significant difference (Fig. 9B). SCV infections yield a mean fold change in CFU/mL
of 1.4 in the absence of the CFTR inhibitor, and 1.4 in the presence of the inhibitor (Fig. 9B).
Intracellular growth was indicated by a positive calculated mean fold-change. All treatment groups
demonstrate a positive fold-change between the two timepoints (Fig 9B). However, the mean foldchanges observed for USA300 ΔmenD are so close to the value 1, that on average they indicate
that intracellular replication is not occurring throughout the population of macrophages. Therefore,
THP-1 macrophages do not contain replicating S. aureus USA300 ΔmenD irrespective of CFTR
inhibition.
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Figure 9. THP-1 derived macrophages do not contain replicating S. aureus USA300 ΔmenD
irrespective of CFTR inhibitor treatment. THP-1 macrophages in the absence or presence of
CFTRinh-172 treatment were infected with either wildtype USA300 (WT) or USA300 ΔmenD at
an MOI of 10, and the gentamicin protection assay protocol was followed as described in the
methods. A) The data represents the mean CFU/mL ± SD. A Kruskal-Wallis nonparametric test
and Dunn’s post-hoc multiple comparison of the means was performed and determined no
significant differences among the means. B) The fold-change in CFU/mL for each biological
replicate was calculated for each treatment group where bacterial counts at 20 h post-infection
were normalized by the bacterial burden at 1.5 h post-infection. The dotted line indicates 1 on the
y axis which represents no replication. Each point represents a biological replicate of the bacterial
strain in a unique population of macrophages. A Kruskal-Wallis nonparametric test and Dunn’s
post-hoc multiple comparison of the means was performed and determined statistical significance,
*P<0.05. Experiments were performed more than 3 times per treatment group.
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3.3.2 Primary human M-CSF-derived macrophages contain replicating USA300 ΔmenD
irrespective of CFTR inhibitor treatment.
Gentamicin protection assays were performed as described above, but here primary human MCSF-derived macrophages were infected with USA300 ΔmenD. To investigate the role of CFTR
in these macrophages infected with this mutant, the macrophages were treated with the CFTR
inhibitor as described above. Wildtype USA300 was used as a control in both macrophage
treatment groups. At 1.5 and 20 hpi, macrophages containing phagocytosed bacteria were lysed
and plated to determine the intracellular bacterial burden (Fig. 10A). This analysis revealed that in
the absence of the CFTR inhibitor, USA300 ΔmenD exhibited a modest decrease in intracellular
bacterial burden between the two timepoints (Fig. 10A).
I determined the fold-change where the bacterial burden counts at 20 hpi were normalized to 1.5
hpi (Fig. 10B). Wildtype infections yield a mean fold change in CFU/mL of 1.9 in the absence of
the CFTR inhibitor, and 4.5 in the presence of the inhibitor, demonstrating a statistically significant
difference (Fig. 10B). SCV infections yield a mean fold change in CFU/mL of 7.6 in the absence
of the CFTR inhibitor, and 4.2 in the presence of the inhibitor (Fig. 10B). Intracellular growth was
indicated by a positive calculated mean fold-change. All treatment groups demonstrate a positive
fold-change between the two timepoints (Fig 10B). Therefore, these data show that primary human
M-CSF-derived macrophages contain replicating USA300 ΔmenD irrespective of CFTR inhibitor
treatment.
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Figure 10. Primary human M-CSF-derived macrophages contain replicating USA300
ΔmenD irrespective of CFTR inhibitor treatment. Primary human M0 macrophages were
infected with either wildtype USA300 (WT) or USA300 ΔmenD at an MOI of 10, and the
gentamicin protection assay protocol was followed as discussed in the methodology section. A)
The data represents the mean CFU/mL ± SD. B) The fold-change in CFU/mL for each biological
replicate was calculated for each treatment group where bacterial counts at 20 h post-infection
were normalized by the bacterial burden at 1.5 h post-infection. The dotted line indicates 1 on the
y axis which represents no replication. Each point represents a biological replicate of the bacterial
strain in a unique population of macrophages. Experiments were performed more than 3 times.
The dotted line represents the y-value 1 and is therefore an indicator of no replication. In panels
A-B, statistical significance was determined by an ordinary one-way nonparametric ANOVA test
with multiple comparisons, * P<0.05.
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3.4

Determining a suitable model to study the intracellular growth of

USA300 ΔmenD
3.4.1 USA300 ΔmenD does not grow in RPMI.
The menD mutant is auxotrophic for menadione and demonstrates slow growth and forms small
colonies on solid media unless it is supplemented with menadione. Remarkably, in the gentamicin
protection assays described above S. aureus lacking menD was able to proliferate within primary
human M-CSF derived macrophages, but not in THP-1 macrophages. This could suggest that S.
aureus USA300 ΔmenD is able to obtain menadione from either the macrophages or the tissue
culture medium. Gentamicin protection assays are routinely performed in the tissue culture
medium that is used to support macrophage growth and to determine whether this culture medium
can supplement the auxotrophy of the menD mutant I performed in vitro growth experiments. In
this experiment wild-type S. aureus USA300 and the menD strain were tested for their ability to
grow in RPMI supplemented with or without FBS. Growth was measured 24 h post-inoculation
which revealed that in RPMI alone, USA300 menD failed to grow whereas wildtype S. aureus
grew to an optical density at 600 nm of 1.3 (Fig. 11A). Similarly, previous unpublished work from
our lab has shown that USA300 hemB does not grow in RPMI alone either (data not shown).
When the media was supplemented with menadione at either 0.8 µg/mL or 0.08 µg/mL, growth of
USA300 menD was restored to levels that were comparable to WT (Fig. 11A). In RPMI
supplemented with 5% (v/v) FBS, USA300 menD was able to grow such that the culture tubes
appeared turbid by eye as compared to the bacteria in RPMI alone. Despite this, quantitation of
the optical densities indicated that growth of USA300 menD was not significantly different in
the presence or absence of FBS (Fig. 11A). In every condition, wildtype S. aureus grew equally
well, indicating the inability of the mutant to grow in RPMI with or without FBS was due to
inactivation of menD alone.
Due to the fact that some, although not significant, growth was observed for USA300 menD
grown in the presence of FBS, I wanted to determine why this growth was occurring. I
hypothesized that the FBS was supplying the mutant with menadione which allowed it to overcome
its auxotrophy by a limited amount. To test this, I wanted to see if the mutant was able to deplete
this potential source of menadione in FBS. I reasoned that if the mutant is grown in RPMI
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containing FBS for long enough, menadione stores will eventually be depleted over time. Thus, I
filter-sterilized that depleted media to remove the bacteria, and then re-inoculated the filtersterilized depleted media with either wildtype or the mutant strain. I predicted that if the mutant
was in fact utilizing and depleting menadione stores in the FBS, the second inoculation by the
mutant would not result in visible growth. Additionally, I predicted that wildtype USA300 would
be able to grow in this filter-sterilized deplete media, because it is capable of growing in minimal
media, therefore WT was used as a growth control. As predicted, the results of these experiments
showed that USA300 menD did not grow in this filter-sterilized deplete media to cause turbidity,
unlike wildtype USA300 which did (Fig. 11A). Despite this, quantitation of the optical densities
indicated that growth of the mutant was not significantly different from wildtype in this treatment
group (Fig. 11A).
TSB is the media used to create overnight cultures for every experiment I perform. When observing
my overnight cultures, I noticed that USA300 menD cultures were much less turbid than those
of wildtype. As seen in the right-most pair of bars in the graph in Fig. 11A, in TSB alone, the
mutant grew to an OD600 that was statistically indistinguishable from the WT, even though there
was a clear visible difference in the OD600 measurements demonstrating that the mutant did not
grow as much as the wildtype (Fig. 11A). To determine whether incubation duration would have
an effect on the growth disparity between the menD mutant and the WT, I extended the overnight
incubation time from 8 h to up to 72 h, and qualitatively observed the cultures intermittently. At
every checkpoint, USA300 menD grew less than wildtype and eventually appeared to stop
growing, while wildtype continued to grow at the later timepoints. Therefore, I hypothesized that
TSB contains limited menadione which supplements the growth of the mutant and allows it to
grow until the menadione is depleted. Thus, I was curious to determine whether supplementation
of TSB with exogenous menadione would allow the mutant to overcome this visible growth
difference (Fig. 11B). Interestingly, in these experiments, the statistical analysis indicates that the
growth of USA300 menD is significantly lower than that of WT in TSB alone (Fig. 11B). As
predicted, these results show that supplementation of TSB with 2 µg/mL of menadione or greater
restores USA300 menD growth to WT levels (Fig. 11B). Therefore, USA300 menD has a
growth defect when grown in TSB, which can be complemented by exogenous menadione.
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After observing that the growth defect of the mutant in TSB could be complemented by increasing
concentrations of exogenous menadione, I wondered whether increasing concentrations of FBS in
RPMI would have a similar effect. If so, this would provide support for my hypothesis that the
tissue culture media was providing nutrients to allow the mutant to overcome its auxotrophy.
Therefore, I inoculated RPMI with increasing concentrations of FBS with the mutant or the WT
control (Fig. 11C). Although qualitatively the mutant’s growth trended upwards with increasing
levels of FBS, growth was always significantly less than WT in every treatment group (Fig. 11C).
Therefore, increasing concentrations of FBS in the tissue culture media do not significantly
increase the growth of USA300 menD. However, due to the qualitatively visible increase in the
mutant’s growth in the presence of FBS throughout these experiments, moving forward I chose to
use RPMI alone as a tissue culture medium in order to avoid the supplementation of the mutant’s
auxotrophy.
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Figure 11. USA300 ΔmenD does not grow in RPMI. A) RPMI was inoculated with either WT
USA300 or USA300 ΔmenD at an OD600 of 0.001. Additional treatment groups include inoculated
RPMI supplemented with either 0.8 µg/mL menadione, 0.08 µg/mL menadione, or 5% FBS. The
fifth treatment group includes RPMI supplemented with depleted 5% FBS (as described in
methods). The final treatment group includes TSB inoculated with either strain as above. B) TSB
in snap cap tubes was inoculated with either WT or the mutant at an OD600 of 0.001. Additional
treatment groups include inoculated TSB supplemented with increasing concentrations of
menadione. C) WT or the mutant S. aureus was cultured in RPMI starting at an OD600 of 0.001.
Additional treatment groups include inoculated RPMI supplemented with increasing
concentrations of FBS. In panels A-C, culture OD600 values were measured at 24 h postinoculation. In panels A-C, a Kruskal-Wallis nonparametric test and Dunn’s post-hoc multiple
comparison of the means were performed and determined statistical significance, *P<0.05,
**P<0.01, ***P<0.001, ****P<0.0001. Experiments were performed at least three times each,
with at least three biological replicates for each treatment group.

3.4.2 Depleted tissue culture media causes morphological defects in RAW 264.7
macrophages.
In the last section I discussed why I decided to utilize RPMI as the tissue culture media in the
experiments I would conduct later on in my study because this media did not supplement the
growth of USA300 ΔmenD. As I was conducting these experiments, I became curious about why
the filter-sterilized deplete media I used in Fig. 11A allowed the WT to grow, but not the mutant.
I wondered whether this media was truly menadione-depleted, and if it could be used as the tissue
culture media during gentamicin protection assays, to serve as a control. Although this deplete
media was filter-sterilized twice to remove the bacteria, it was possible that bacterial products such
as toxins would still be present in the media. Therefore, I needed to determine if this media had
harmful effects on macrophages.
For this purpose, RAW 264.7 murine macrophages (RAWs) were investigated due to their ease of
use and reproducibility of observations in primary human macrophages. As a control, RAWs were
cultured in RPMI supplemented with 5% (v/v) FBS or were grown in the conditioned and filtersterilized depleted medium. At 12 h macrophages were stained with the vital dye propidium iodide
to label necrotic cells and were visualized by fluorescence microscopy. These results showed that
after being cultured in the depleted medium, RAW macrophages remained refractory to PI staining
similar to RAW cells cultured in fresh culture (Fig. 12). As a PI positive control, macrophages
were cultured in fresh media and then fixed with 4% paraformaldehyde to cause cell death,
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indicated in red (Fig. 12). Despite the macrophages remaining viable as indicated by the lack of PI
staining, comparison of the cells cultured under these conditions to those in the control, revealed
that the macrophages grown in the conditioned medium were altered morphologically (Fig. 12).
Thus, I decided not to use this deplete media in my future experiments.

PI stain

Merge

Fixed cells

Deplete media

Control

DIC

Figure 12. Depleted tissue culture media causes morphological defects in RAW 264.7
macrophages. RAW 264.7 macrophages were cultured in RPMI + 5% FBS for 12 hours in panels
“Control” and “Fixed cells”. In “Deplete media,” macrophages were cultured in RPMI
supplemented with depleted 5% FBS for 12 h. To deplete the media, RPMI + 5% FBS was
inoculated with USA300 ΔmenD at an OD600 of 0.001 for 6 h. Then the culture was centrifuged,
the pellet was discarded, and the supernatant was filter sterilized twice. “Fixed cells” serve as a
representative image of the positive control for the propidium iodide (PI) stain. Cells were fixed
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with 4% paraformaldehyde to cause cell death, visualized in red. “Control” macrophages serve as
a representative image of the negative control for the PI stain. In all three panels, macrophages
were then treated with 0.1% (v/v) Triton X-100 for 2 min to permeabilize cell membranes, then
stained with PI for 5 min, and imaged immediately. Images were taken at 100x magnification by
a widefield fluorescent microscope. Experiments were performed 3 times, with 3 biological
replicates per experiment.

3.4.3 USA300 ΔmenD is not hemolytic.
Given that the conditioned deplete medium altered the morphology of RAW macrophages and was
generated using the menD mutant, I wanted to determine whether the altered morphology was due
to toxin production. It is known that SCVs secrete reduced α-hemolysin (α-toxin) as compared to
wild-type S. aureus. To determine whether menD mutant conditioned medium contained -toxin
I analysed human red blood cell (RBC) lysis through ultraviolet-visible (UV-Vis) spectroscopy
which can be used to detect the presence of heme liberated through hemolysis, demonstrated by
the presence of a Soret peak at ~400 nm (185). As described in the methodology, RBC containing
cultures were inoculated with stationary phase cultures of either WT USA300 (positive hemolysis
control), USA300 Δagr (negative hemolysis control), or USA300 menD (Fig. 13). USA300
ΔmenD, unlike WT USA300 and the triton positive hemolysis control, does not exhibit the Soret
peak (Fig. 13A). As a hemolysis-negative control, USA300 Δagr was used to demonstrate the
effects of a known non-hemolytic strain of USA300, and therefore does not exhibit the Soret peak,
similar to USA300 ΔmenD (Fig. 13B). Therefore, these results show that USA300 ΔmenD is not
hemolytic, and therefore does not secrete the same amount of α-toxin as the WT (Fig. 13).
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A) USA300 ΔmenD
B) USA300 Δagr
C) WT USA300 #1
D) Triton control
E) WT USA300 #2

Soret peak

Figure 13. USA300 ΔmenD is not hemolytic. This multigraph compiles a representative multiple
scanning UV-vis absorbance spectroscopy reading of various indicated treatment groups. In each
treatment group, isolated red blood cells in a designated volume of TSB were inoculated with the
indicated strains: A) USA300 ΔmenD, B) USA300 Δagr negative control, C) low concentration
USA300 positive control, D) triton positive control, E) high concentration USA300 positive
control. After 20 hours of incubation at 25°C, the absorbance of these solutions was measured.
Experiments were performed 3 times, with three biological replicates for each treatment group.
The detailed protocol is provided in the methods. The presence of a Soret peak, located in the
highlighted region on the graph, indicates hemolysis.

3.4.4 Exogenous menadione causes morphological defects and death in RAW 264.7
macrophages.
As I continued to investigate how I could optimize the protocols of my gentamicin protection
assays to study the intracellular growth of USA300 ΔmenD, I wanted to determine whether
exogenous menadione present in the media would affect the intracellular growth of the SCV. I did
not know why the SCV was capable of growing and was still trying to determine if the SCV’s
auxotrophy was being supplemented by menadione in the media or the macrophage. Thus, I
hypothesized that if I could show that exogenous menadione could increase the intracellular
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bacterial burden of the SCV, this may provide support to show that the growth was due to traces
of menadione in the tissue culture media. Published work has shown that menadione may be
cytotoxic (186). Therefore, I wanted to determine whether menadione, used at the concentrations
that complement menD mutant growth, could be cytotoxic to RAW macrophages. PI stains were
performed as before on RAWs cultured in RPMI supplemented with increasing concentrations of
menadione (Fig. 14).
All RAWs were cultured in RPMI supplemented with 5% (v/v) FBS for 12 h, in the absence or
presence of menadione at increasing concentrations. At 12 h macrophages were stained with the
vital dye propidium iodide to label necrotic cells and were visualized by fluorescence microscopy.
These results showed that after being cultured in higher concentrations of menadione (8 µg/mL),
RAW macrophages retained the PI stain, similar to the RAWs that were killed by 4%
paraformaldehyde fixative to serve as a PI positive control, indicated in red (Fig. 14). Macrophages
treated with lower concentrations of menadione (0.8 and 0.08 µg/mL) were PI negative (Fig. 14).
Despite the macrophages remaining viable as indicated by the lack of PI staining, comparison of
the cells cultured under these conditions to those in the “no menadione” control, revealed that the
macrophages grown in the conditioned medium were altered morphologically (Fig. 14). These
cells looked significantly rounder and many had detached from the substratum, indicating the
effects of media toxicity (Fig. 14). Therefore, the results of these experiments showed that
exogenous menadione is cytotoxic and causes morphological defects to RAWs at the
concentrations which are optimal to supplement growth of the SCV. Thus, I decided against using
exogenous menadione during my future macrophage infections to avoid the confounding effects
that these morphological changes could have had on the intracellular bacterial burden I would
observe.
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Figure 14. Exogenous menadione causes morphological defects and death in RAW 264.7
macrophages. RAW 264.7 macrophages were grown in RPMI supplemented with 5% FBS for
12 hours. The top panel (Fixed cells) serves as a representative image of the positive control for
the propidium iodide (PI) stain where cells were fixed with 4% paraformaldehyde to cause cell
death, visualized in red. In the next four panels, macrophage media was supplemented with either
8, 0.8, 0.08 μg/mL of menadione, or no menadione as a control. In all panels at 12 h, macrophages
were treated with 0.1% triton for 2 min to permeabilize cell membranes, then stained with PI for
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5 min, and imaged immediately. Images were taken at 100x magnification by a widefield
fluorescent microscope. Experiments were performed 3 times, with 3 biological replicates per
experiment.

3.5

Investigating the intracellular growth of USA300 ΔmenD

3.5.1 USA300 ΔmenD exhibits delayed intracellular growth within RAW 264.7 murine
macrophages.
Next, I wanted to investigate the ability of USA300 ΔmenD to proliferate within RAWs. To
eliminate the adverse effects of adding menadione or using a conditioned deplete medium I opted
to perform infections in serum-free RPMI which does not support the growth of USA300 ΔmenD
in vitro. Gentamicin protection assays using RAWs that were infected with WT USA300 and
USA300 ΔmenD were performed and the ability of the bacteria to replicate was determined (Fig.
15). WT USA300 had replicated intracellularly as indicated by the 2.5 mean fold-change in
bacterial burden at 12 h post-infection as compared to 1.5 h. In contrast at the same time point the
calculated mean fold-change in bacterial burden for USA300 ΔmenD bacteria was 0.9 indicating
intracellular bacteria are being killed (Fig. 15A). To determine whether USA300 ΔmenD can
eventually grow, intracellular infections were repeated and incubated until 18-24 hpi. Interestingly,
with prolonged incubation the menD mutant was able to proliferate intracellularly similar to WT
USA300 (Fig. 15B). At the later timepoints, WT USA300 had replicated intracellularly as
indicated by the 24.2 mean fold change in bacterial burden, and USA300 ΔmenD had replicated
intracellularly as indicated by the 13.3 mean fold-change (Fig. 15B).
To confirm that USA300 ΔmenD was actually proliferating while remaining intracellular,
eFluor-670-based proliferation assays were performed (Fig. 15C). The experiments showed that
at 12 and 18 hpi the mutant had replicated intracellularly as indicated by the presence of GFPexpressing cocci that are proliferation dye negative within a subset of the macrophages (Fig. 15C).
To quantify the proportion of macrophages that contain intracellular replication, the fraction of
macrophages containing replicating USA300 ΔmenD was determined and normalized to the
number of macrophages containing replicating WT (control), to create an index (Fig. 15D-E). This
index demonstrates that at 12 hpi, the mutant exhibits intracellular replication within a smaller
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subset of the macrophage population (Fig. 15E). Therefore, these results show that there is a
temporal delay for intracellular replication of USA300 ΔmenD when compared to the control.
A

B

C
TMR-WGA

S. aureus/GFP
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S. aureus/eFluorTM-670 Fluorescence Merge

Figure 15. USA300 ΔmenD exhibits delayed intracellular growth within RAW 264.7 murine
macrophages. RAW 264.7 macrophages were infected with either USA300 or USA300 ΔmenD
at an MOI of 30, and the gentamicin protection assay protocol was followed as discussed in the
methodology section. The data represents the fold-change of CFU/mL between 1.5 and 12 hpi (A)
or 18-24 hpi (B) for each biological replicate. Each data point represents a biological replicate of
the bacterial strain in a unique population of macrophages. Experiments were performed more than
3 times per treatment group. The dotted line represents the y-value 1 and is therefore an indicator
of no replication. C) Representative widefield microscopy images demonstrate RAWs infected
with USA300 ΔmenD following eFluor-670-based proliferation assay protocols viewed in
brightfield (first panel) and multiple fluorescence channels, at 12 and 18 hpi. WGA stained
macrophage plasma membranes are shown in red fluorescence, eFluorTM-670 positive S. aureus
in far-red (blue), and GFP-expressing S. aureus in green. White arrows indicate green clusters of
S. aureus, negative for proliferation dye, thus demonstrating intracellular replication. D)
Coverslips from the eFluor-670-based proliferation assays were scanned microscopically to
quantify the number of macrophages containing intracellular replication. E) An index was created
by normalizing the mutant values in (D) to those of the WT. An unpaired Mann-Whitney
nonparametric two-tailed test was performed and determined statistical significance, **P<0.01,
***P<0.001. Images are representative of at least three independent experiments, scale bars equal
10 μm.

3.5.2 USA300 ΔmenD does not grow under gentamicin protection assay tissue culture
conditions in the absence of macrophages.
My results above show that as a menadione auxotroph, USA300 ΔmenD doesn’t grow in vitro
unless it is supplemented with menadione. The results of my gentamicin protection assays
demonstrate however, that this mutant is able to grow intracellularly. Before the gentamicin
protection assay is performed, macrophages are seeded in a 12-well plate and they are cultured in
RPMI supplemented with FBS. My results suggest that this media may conceivably contain traces
of menadione, which allow for a very low level of growth that is qualitatively observable.
Therefore, I was interested in investigating whether the intracellular growth observed during these
assays, was due to traces of extracellular menadione leftover from the tissue culture media.
I performed mock gentamicin protection assays in the absence of macrophages, as detailed in the
methods (Fig. 16). These results show that whether or not FBS is ever present in the tissue culture
media, and whether there is a PBS wash or not prior to inoculation, these differences in the protocol
do not change the growth of the mutant (Fig. 16). Therefore, the gentamicin protection assay
protocol does not provide traces of menadione that can supplement the auxotrophy of the mutant.
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Figure 16. USA300 ΔmenD does not grow under gentamicin protection assay tissue culture
conditions in the absence of macrophages. Gentamicin protection assay mock infections were
performed as described in detail in the methods. 12-well tissue culture plates were filled with 1
mL of either RPMI supplemented with 5% FBS (FBS), or RPMI (SF) and incubated. Afterwards,
the media was removed from the wells and the wells were either washed with PBS or left
unwashed. RPMI inoculated with either USA300 or USA300 ΔmenD at an OD600 of 0.001, was
added to each well. To serve as a positive growth control for USA300 ΔmenD, designated wells
contained menadione. The plates were then incubated for 24 h in a 37°C static incubator. Endpoint
OD600 readings were then measured for each well. Each dot represents a biological replicate, where
experiments were performed more 3 times per treatment group and each experiment contained 3
biological replicates. A Kruskal-Wallis nonparametric test and Dunn’s post-hoc multiple
comparison of the means were performed for treatment groups inoculated with the mutant, and
determined significance, **P<0.01, ***P<0.001. Blue asterisks compare USA300 ΔmenD means
to the USA300 ΔmenD SF menadione treatment group, black asterisks compare USA300 ΔmenD
means to the USA300 ΔmenD FBS menadione treatment group.
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3.5.3 Acidity and low oxygen availability do not induce the growth of USA300 ΔmenD in
vitro.
In an attempt to understand how USA300 ΔmenD are able to grow, albeit at reduced levels inside
RAW macrophages, I sought to determine how changes in pH or oxygenation affect the mutant’s
growth. Since the phagosome is an acidic environment that is also subject to dynamic redox
changes, I evaluated the influence of pH and redox variables on growth of WT USA300 and
USA300 ΔmenD bacteria in serum free RPMI as detailed in the methods (Fig. 17A). WT was used
as a control and was either grown in cultures containing exogenous menadione or not containing
exogenous menadione (Fig. 17A). The growth of the WT decreased in both treatment groups as
the acidity increased (Fig. 17A). This was also seen for USA300 ΔmenD inoculated tubes in the
presence of exogenous menadione (Fig. 17A). However, USA300 ΔmenD in the absence of
menadione did not grow at all, irrespective of the differences in pH (Fig. 17A). Therefore, these
results show that increasing acidity did not induce the growth of the mutant in vitro.
Next, I considered how oxygenation might impact growth of USA300 ΔmenD. As mentioned, the
phagosome can have dynamic changes in redox activity which could affect the mutant’s growth.
Moreover, the in vitro growth experiments performed in the previous experiments were all
performed under aerobic conditions (e.g. in shaking incubator), whereas gentamicin protection
assays are performed under static conditions and at 5% CO2. Thus, I investigated whether growth
of the menD mutant is impacted by aeration in vitro (Fig. 17B). The same control strains were used
as in the previous panel, and cultures were grown either in a shaking aerobic incubator, a static
aerobic incubator, or in a static microaerophilic incubator as detailed in the methods (Fig. 17B).
The WT strain grew in all three aeration conditions, irrespective of the presence of exogenous
menadione in the culture (Fig. 17B). USA300 ΔmenD similarly grew in all three conditions when
supplemented with exogenous menadione (Fig. 17B). However, USA300 ΔmenD did not grow at
all in either of the conditions if exogenous menadione was absent (Fig. 17B). These results show
that low oxygen availability in the form of static or microaerophilic incubator conditions does not
induce the growth of the mutant.
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Figure 17. Acidity and low oxygen availability do not induce the growth of USA300 ΔmenD
in vitro. RPMI buffered with 0.1 M tris-maleate was inoculated with USA300 or USA300 ΔmenD
at an OD600 of 0.001, in the presence or absence of 0.8 µg/mL menadione. A) Treatment groups
were maintained at a pH of 7.5, 6.5 or 5.5. Tubes were incubated at 37°C for 24 h, and OD600
measurements were taken. A Kruskal-Wallis nonparametric test and Dunn’s post-hoc multiple
comparison of the means were performed for treatment groups inoculated with the mutant, and
determined significance, *P<0.05, **P<0.01. B) Tubes were incubated at 37°C for 24 h in either
a shaking aerobic incubator, static aerobic incubator, or in a static microaerophilic incubator. A
one-way ANOVA was performed to determine if differences between USA300 ΔmenD and
USA300 within each treatment group were statistically significant ****P<0.0001. For both graphs,
each dot represents a biological replicate, where experiments were performed at least 3 times.
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3.5.4 Intracellular growth of USA300 ΔmenD is not due to an alternate menaquinone
biosynthesis pathway downstream of chorismate synthase
Despite its auxotrophy, USA300 ΔmenD is capable of growing intracellularly after a temporal
delay when compared to the WT. To continue investigating how this mutant overcomes its
auxotrophy, I considered whether the mutant was producing menaquinone (an isoprenylated form
of menadione) through an alternative pathway which was somehow induced by the intracellular
environment. For example, the futalosine pathway is used by Helicobacter pylori to produce
menaquinone (187). This pathway is downstream of chorismate synthase, an enzyme that is also
upstream of the men pathway in USA300 to produce menaquinone. To determine whether USA300
ΔmenD produces menaquinone using an alternative biosynthetic pathway downstream of
chorismate synthase, I performed gentamicin protection assays on RAWs using a mutant carrying
a transposon inserted in the aroC gene that encodes chorismate synthase (Fig. 18). This mutant,
called USA300 aroC::ΦNΣ, when streaked on nutrient rich agar plates grows similar to other
SCVs, such as USA300 ΔmenD.
Using this mutant for macrophage infections it was evident that USA300 aroC::ΦNΣ demonstrates
a similar delay in intracellular replication akin to USA300 ΔmenD (Fig. 18). WT USA300 had
replicated intracellularly as indicated by the 5.7 mean fold-change in bacterial burden at 12 h postinfection as compared to 1.5 h. In contrast at the same time point the calculated mean fold-change
in bacterial burden for USA300 aroC::ΦNΣ bacteria was 0.6 indicating intracellular bacteria are
being killed (Fig. 18A). To determine whether USA300 aroC::ΦNΣ can eventually grow,
intracellular infections were repeated and incubated until 24 hpi. Interestingly, with prolonged
incubation the aroC mutant was able to proliferate intracellularly similar to WT USA300 (Fig.
18B). At the later timepoints, WT USA300 had replicated intracellularly as indicated by the 63.3
mean fold change in bacterial burden, and USA300 aroC::ΦNΣ had replicated intracellularly as
indicated by the 17.7 mean fold-change (Fig. 18B). Since the disruption of chorismate synthase
did not hinder intracellular growth, I conclude that the intracellular growth of USA300 aroC::ΦNΣ
is not due to an alternate menaquinone biosynthesis pathway downstream of chorismate synthase.
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Figure 18. Intracellular growth of USA300 ΔmenD is not due to an alternate menaquinone
biosynthesis pathway downstream of chorismate synthase. RAW 264.7 macrophages were
infected with either USA300 or USA300 aroC::ΦNΣ at an MOI of 30, and the gentamicin
protection assay protocol was followed as discussed in the methods. The data represents the foldchange of CFU/mL between 1.5 and 12 hpi (A) or 24 hpi (B) for each biological replicate. Each
data point represents a biological replicate of the bacterial strain in a unique population of
macrophages. Experiments were performed 3 times per treatment group. The dotted line represents
the y-value 1 and is therefore an indicator of no difference in fold-change between the two
timepoints. Statistical significance was determined by an ordinary one-way nonparametric Anova
test with multiple comparisons, ** P<0.01.

3.5.5 RAW macrophages do not supply menaquinone or menaquinone precursors to
supplement the growth of USA300 ΔmenD.
To continue investigating how USA300 ΔmenD is capable of growing intracellularly, I considered
whether the RAWs were supplying menaquinone or menaquinone precursors to supplement the
growth of USA300 ΔmenD. Although mammalian cells do not produce menaquinone, I
hypothesized that the macrophages could store menaquinone or menaquinone precursors that are
taken up from the tissue culture medium they are cultured in. To test this idea, I added RAW
macrophage lysates to RPMI in 13 mL polypropylene snap-cap tubes (Sarstedt) and inoculated
these tubes with USA300 ΔmenD, for growth analysis (Fig. 19A). The same was done with WT
and USA300 aroC::ΦNΣ, to serve as strain controls (Fig. 19A). For treatment controls, I inoculated
RPMI alone, RPMI supplemented with exogenous menadione, and RPMI supplemented with
menadione as well as a lysate vehicle control to ensure that the lysing process didn’t have
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confounding effects on my results (Fig. 19A). As predicted, the mutants did not grow in RPMI
alone, unless they were supplemented with exogenous menadione (Fig. 19A). In RPMI containing
macrophage lysates, the mutants did not grow either (Fig. 19A). These results were in contrast to
those seen for WT, which grew in both those conditions (Fig. 19A). All three strains grew in the
lysate vehicle control group, due to the presence of exogenous menadione; thus, the lytic reagents
were not a hindering factor for the growth of the mutants (Fig. 19A). Therefore, these results show
that RAWs lysates do not supplement the growth of either mutant (Fig. 19A).
Next, I considered that the macrophages in my infections are exposed to the bacteria and bacterial
products for an extended period of time before they eventually support the growth of USA300
ΔmenD 18-24 hpi. Therefore, I was interested in determining whether the direct stimulation of
macrophages could be accelerating the growth of these intracellular bacteria. This would make
sense mechanistically if due to the presence of USA300, the macrophages secrete a supplementing
metabolite into the extracellular milieu, which can then be transported to the intracellular
auxotroph. An alternative explanation could be that this stimulus would result in the macrophages
making intracellular menaquinone or menaquinone precursors more accessible by the intracellular
auxotroph.
Therefore, as detailed in the methods, I stimulated RAWs with heat-killed USA300 ΔmenD, then
isolated the macrophage supernatant and lysates and added these to separate RPMI cultures
inoculated with live USA300 ΔmenD, then measured the endpoint OD600 after 24 h of incubation
(Fig. 19B). The same was done with WT USA300, and USA300 ΔmenD in the presence of
exogenous menadione, to serve as strain controls (Fig. 19B). As a treatment control, I also did the
same thing with unstimulated macrophage lysates and supernatants (Fig. 19B). Additionally, to
ensure that the stimulus did not contain any traces of live bacteria, the heat-killed S. aureus was
added to RPMI cultures which were then inoculated with the aforementioned strains (Fig. 19B).
These results show that USA300 ΔmenD did not grow in cultures containing lysates or
supernatants which were stimulated or unstimulated (Fig. 19B). Additionally, USA300 ΔmenD
did not grow in the stimulus control condition, indicating that this stimulus itself did not have any
confounding effects on the mutant (Fig. 19B). These results were in contrast to USA300 ΔmenD
in the presence of menadione and the WT strain which grew in all conditions (Fig. 19B). Therefore,
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these results show that the presence of this stimulus does not alter the composition of the
supernatant or lysates, such that they supplement the growth of the mutant (Fig. 19B).
A

B

Figure 19. RAW macrophages do not supply menaquinone or menaquinone precursors to
supplement the growth of USA300 ΔmenD. RPMI was inoculated with either USA300, USA300
aroC::ΦNΣ, or USA300 ΔmenD (with or without menadione supplementation) at a starting OD600
of 0.001. Cultures were incubated for 24 h in a static 37°C incubator and endpoint OD600
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measurements were graphed. RAW 264.7 macrophages were seeded to reach 90% confluency in
a T75 flask. Each dot represents a biological replicate, where experiments were performed more
than 3 times per treatment group. A) The media surrounding the macrophages (supernatant) was
discarded, and the macrophages were washed with 1X PBS. Macrophages were lysed with 0.001%
triton and ddH20 for 30 min. Lysates were divided equally into each treatment group as labeled in
the graph. A Kruskal-Wallis nonparametric test and Dunn’s post-hoc multiple comparison of the
means were performed for treatment groups inoculated with the mutant, and determined
significance, *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. B) Macrophages were seeded as
before, then were either “stimulated” by the addition of by heat-killed USA300 ΔmenD to the
tissue culture medium for 24 h, or unstimulated (no additional treatment to culture). The
supernatant and lysates were collected from either macrophage treatment group, then equally
divided and added to the treatment groups of inoculated RPMI, as described in the graph. An
ANOVA was performed to determine statistical significance *P<0.05, **P<0.001, ****P<0.0001.
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Chapter 4: Discussion and Future Directions
During the last few decades as CF patient life-spans are increasing, the prevalence of CF has also
been steadily increasing in Canada (130). The most common cause of death for CF patients is
caused by compromised pulmonary function due to chronic bacterial infection and inflammation
(130). Consequently, many researchers have directed their efforts to try to prevent the onset of
bacterial infection in the CF patient population (130). In Canada, S. aureus is the most prevalent
bacterium isolated from the CF lung, and the prevalence of MRSA colonization in CF patients has
been increasing (130). S. aureus SCVs emerge in the inflamed environment of the CF lung, and
seventy percent of Canadian CF patients are colonized by SCVs (120, 151, 152). Therefore, it is
important to better understand the mechanisms underlying the pathogenesis of MRSA in the
context of CF patient immunity (130). Although many studies have investigated the role of CF
macrophages in response to bacterial infection, these have yielded contradictory findings and no
consensus on whether CF macrophages are actually impaired for bacterial clearance. While some
research suggests that a disruption in the macrophage’s CFTR results in inherent defects in its
response to bacterial infection, other work posits that CFTR serves no role in the macrophage’s
susceptibility to infection (162–166). For proponents of the former hypothesis, there is currently
no consensus on the mechanisms that are suggested to underly the CF macrophage’s inherent
immune defects. Alarmingly, despite the importance of S. aureus in CF infections, little research
has been done to elucidate the interactions of MRSA and its SCVs with CFTR-deficient
macrophages.

4.1

Do CFTR-deficient macrophages exhibit inherent defects in their ability to

traffic S. aureus and inhibit its intracellular replication?
The first aim of my project was to determine whether CFTR-deficient macrophages exhibit
inherent defects in their ability to traffic S. aureus to the phagolysosome and inhibit intracellular
replication. My results demonstrate that CFTR-deficient macrophages are able to phagocytose WT
MRSA (USA300), in a manner that reflects CFTR competent macrophages. Upon phagocytosis,
in a small subset of the macrophage populations USA300 is able to replicate intracellularly
following a significant delay (>12 hpi). This was shown in three different types of macrophages,
CFTR inhibitor treated THP-1 macrophages and primary human M-CSF-derived macrophages,
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and primary M-CSF differentiated macrophages derived from CF patients. In comparison to the
untreated control, fewer intracellular bacteria were recovered from the CFTR inhibitor treated
THP-1 macrophages. In contrast, CFTR inhibitor treated primary human M-CSF-derived
macrophages were more permissive to bacterial growth than untreated control macrophages.
Although primary M-CSF differentiated macrophages derived from CF patients do appear to be
trending towards being more permissive to bacterial growth in comparison to the control non-CF
macrophages, there was no significant difference between these values.
The variability in these results among the different types of macrophages demonstrates the
importance of using multiple iterations of the same model to test these host-cell interactions.
However, based on these results alone it is difficult to form a consensus of whether CFTR
deficiency renders macrophages more susceptible to USA300 intracellular replication. These
experiments were performed using gentamicin protection assays, which assess the amount of
intracellular replication occurring within an entire population of macrophages. It is important to
consider that there is physiological and functional heterogeneity among macrophages, and this
heterogeneity can affect phagocytic uptake, intracellular trafficking, and energy metabolism (188,
189). Additionally, there is also heterogeneity among different phagosomes within macrophages,
as no two phagosomes are created through the exact same process even if the phagocytosed particle
is identical (190). To obtain better resolution in light of this heterogeneity, the results obtained
from these experiments can be paired with microscopic single-cell analysis techniques.
To continue the investigation of the role of CFTR in these host-cell interactions future experiments
must be performed. For example, if CFTR-deficient macrophages are more susceptible to S. aureus
intracellular replication, a larger fraction of an infected macrophage population may contain
replicating bacteria in comparison to normal macrophages. To determine if this is true, eFluor670-based proliferation assays can be used to quantify the fraction of macrophages that contain
intracellular replication within these two different populations. It is also important to determine
what niche is being occupied by intracellular S. aureus when inside these CFTR-deficient
macrophages. Our lab’s previous published work demonstrates that in primary human M-CSFderived macrophages and RAW 264.7 macrophages, USA300 can begin replicating while inside
acidic LAMP-1 positive phagosomes (112, 191). Whether this is true for CFTR-deficient
macrophages must be determined. This can be done through immunostaining endogenous LAMP78

1 in macrophages which have been infected with GFP-expressing eFluorTM-670 dyed S. aureus
and visualizing them through confocal fluorescence microscopy. If clusters of GFP-positive
eFluorTM-670 negative cocci are located inside LAMP-1 positive compartments, this would
indicate that the intracellular niche of phagocytosed S. aureus is unaffected by the macrophages
CFTR deficiency.
Previous studies suggest that CFTR-deficient and CFTR inhibitor treated macrophages exhibit
delays in phagosomal maturation (168, 176). In order to investigate whether the CFTR-deficient
macrophages in my study demonstrate differences in the intracellular trafficking of S. aureus, a
future study could use dextran pulse-chase experiments. In these experiments, widefield
fluorescence microscopy could be used to try to visualize the colocalization of fluorescent dextran
ingested by macrophages which have been infected with GFP-expressing eFluorTM-670 dyed S.
aureus, as previously described by our lab (112). Live-cell imaging could help to elucidate any
temporal or locational differences in trafficking between CFTR-deficient and normal
macrophages.
Another proposed mechanism said to underly inherent CFTR-dependent macrophage defects is pH
regulation of the phagosome and phagolysosome. Many studies have suggested that in CFTRdeficient macrophages, these compartments are less acidic than normal, thus resulting in decreased
microbicidal capability (163, 164, 167). To investigate this scenario experiments should be
performed using acidotropic dyes such as Lysotracker Green DND-26 to look for any differences
in colocalization with S. aureus between CFTR-deficient and normal macrophages. Furthermore,
FITC dextran pulse chase experiments could also be performed to permit ratiometric pH measures
of phagosomes containing S. aureus in CF and non-CF macrophages to directly measure the pH
of S. aureus-containing phagolysosomes between these cells. If phagolysosomes in CFTRdeficient macrophages are indeed less acidic, then it would be expected that a smaller percentage
of cocci will colocalize with Lysotracker and the measured pH will be more alkaline as compared
to CFTR competent macrophages.
My results show that CFTR inhibitor treated primary human M-CSF-derived macrophages are
more permissive to bacterial growth than the untreated control macrophages. However, these
results were different from those seen in the inhibitor treated THP-1 macrophages and primary M-
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CSF differentiated macrophages derived from CF patients. Past studies have suggested that
phagocytic uptake is reduced by CFTR dysfunction in macrophages (171, 172, 174). In contrast,
my data shows that the phagocytic index, measured by the bacterial burden recovered at 1.5 hpi,
does not differ for S. aureus irrespective of CFTR deficiency. This is true for all macrophage types
used in my study. The variability in my results is therefore not due to differences in phagocytic
uptake across the three cell types.
While discussing the heterogeneity in macrophages, it is important to also consider the polarization
states of the primary macrophages that were used in this study. Here, I differentiated my
macrophages to an M0 (naïve, uncommitted) state by using M-CSF to regulate their differentiation
into “anti-inflammatory” macrophages which resemble M2 macrophages in function and
phenotype (192). M-CSF derived macrophages are known to be involved with phagocytosis and
the release of anti-inflammatory cytokine IL-10, but can also be subsequently differentiated into
pro-inflammatory M1 macrophages when stimulated with inflammatory factors (192). Therefore,
it is difficult to conclusively state what the state of the macrophages were in each experiment,
without performing additional analyses to confirm. For example, flow cytometry can be used to
identify M1 and M2 surface receptor expression, such as CD80 and CD163 respectively. Since
M1 macrophages exhibit an oxidative burst, if certain populations in the pooled data contained M1
macrophages, this could skew the data. Therefore, follow up experiments must be performed with
all three confirmed polarizations states of these macrophages to see if these results are recapitulated
and if they differ based when the polarization state is changed.
Above, I mentioned the potential sources and effects of macrophage heterogeneity. It is also
important to discuss CFTR defect heterogeneity. Across all three macrophage types, there is likely
heterogeneity with regards to how much CFTR is expressed on the plasma membrane (193). In the
CFTR inhibitor treated macrophages, there is heterogeneity with regards to how much inhibition
occurs on each macrophage within a treated population (178). When receiving CF patient blood
samples, all patient information, including age, sex, and CFTR mutation type was not provided.
Therefore, in the CF patient derived macrophages there is likely some heterogeneity with regards
to the kinds of CFTR mutation present in this data. CF disease presentation is highly heterogeneous
within the CF population, and this is in part due to the spectrum of CFTR mutation types (194).
For example, mutations can lead to a complete loss of function or impaired function of the protein
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(194). In the past, CFTR genotypes were said to be poorly correlated with pulmonary disease
severity (195). However, more recent studies demonstrate that there may be correlations between
certain mutation types with the severe manifestation of pulmonary disease (194). Therefore, it is
plausible that the variation seen in the results obtained from the three macrophages types in my
study, is due to differences in CFTR expression and inhibition.
Future experiments could investigate this by performing western blots using CFTR antibodies, to
compare the CFTR expression across the three macrophage types used. During these experiments,
macrophages from each cell type must be counted to obtain the same cell number, and then lysed
and treated with a CFTR antibody. The non-inhibitor treated macrophages from each cell type
should be used as controls. In fact, I was planning on doing this prior to COVID-19 lab closures
and had ordered CFTR Mouse anti-Human/Mouse/Rat, Clone: M3A7, Mouse Monoclonal
Antibody (Invitrogen™). Alternatively, the CFTR on these cells can be immunostained and
visualized using fluorescence microscopy to obtain a qualitative assessment of CFTR placement
and abundance on the cell membrane.
Small colony variants of S. aureus are frequently recovered from the CF lung, a highly
inflammatory and stressful environment which selects for their emergence (114). Although host
tissues may be effectively cleared of wildtype S. aureus, SCVs continue to be isolated from these
tissues, which is said to be due to their ability to persist within intracellular niches (91, 119–121).
Despite their importance, how these SCVs interact with macrophages is poorly understood.
Therefore, the second objective of my study was to determine if SCVs differ in intracellular
survival and trafficking from wild-type S. aureus upon interaction with macrophages. To
investigate this objective, I performed the same experiments as objective one with the hemB and
menD mutants of USA300.
Interestingly my results demonstrate that, in contrast to previously published data, staphylococcal
SCVs replicate intracellularly instead of simply persisting. In this study, THP-1, primary human
M-CSF-derived macrophages, and RAW macrophages are all able to phagocytose SCVs.
However, my results also show that in certain cases, these SCVs differ from WT S. aureus upon
interaction with macrophages. Upon phagocytosis, in a small subset of the macrophage
populations USA300 ΔhemB is phagocytosed and is able to replicate intracellularly following a
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delay of around 12-20 hpi, similar to the results obtained for WT USA300. These results were seen
across all three macrophage types.
USA300 ΔmenD was only used to infect RAW, THP-1, and primary human M-CSF-derived
macrophages obtained from healthy donors, due to the limited CF patient samples. USA300
ΔmenD is able to replicate intracellularly following a delay of around 20 hpi, in the RAW and
primary human M-CSF-derived macrophages, but not in the THP-1s. Interestingly, there is a
significant temporal delay in the onset of intracellular replication of USA300 ΔmenD in RAWs,
when compared to WT S. aureus USA300. In fact, at 12 hpi the majority of phagocytosed USA300
ΔmenD appears to be killed, as indicated by the negative average fold-change in bacterial burden.
Although CFTR deficiency appears to have an effect, albeit minor, on the bacterial burden of
macrophages infected with WT USA300, it has no significant effect on the bacterial burden of
macrophages infected with either SCV.
Upon analyzing these results, a few questions must be discussed and investigated further:
1. Why does USA300 ΔmenD differ from WT and USA300 ΔhemB during its
interaction with the macrophage?
2. How are these SCVs capable of overcoming their auxotrophy?
3. Does CFTR deficiency affect SCVs in the way that it effects WT USA300?

4.2

Why does USA300 ΔmenD differ from WT and USA300 ΔhemB during

its interaction with the macrophage?
It is evident that USA300 ΔmenD differs from USA300 ΔhemB and WT in its ability to replicate
within THP-1 macrophages. In THP-1s USA300 ΔmenD does not replicate in these macrophages,
and instead persists intracellularly as is described in the literature. These observations corroborate
the results of a study which demonstrates that the thymidine auxotroph SCV of S. aureus persists
in THP-1 macrophages for a much longer period of time than the wildtype strain (122).
Additionally, a study published by Garcia et al. (2012) similarly demonstrates that while the hemB
mutant and WT S. aureus replicate inside THP-1 phagocytes, the menD mutant does not (196).
Therefore, these differences of growth may be due to a property of the THP-1 macrophage, a
property of the menD SCV, or a combination of the two.
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THP-1 macrophages in this study were differentiated to the M0 state using PMA, but are known
to be differentiated to the classically activated phenotype when in the presence of bacteria (197,
198). If the THP-1s in this study were classically activated, this would mean that they likely
exhibited an oxidative burst. Initially, I considered whether USA300 ΔmenD is more sensitive to
the respiratory burst than the other two strains, and thus it is unable to survive and replicate
intracellularly. This would have supported the hypothesis set forth by Garcia et al. (2013), which
suggests that the menD mutant is hypersusceptible to oxidant species (199). However, this would
not explain why USA300 ΔmenD was able to survive and replicate inside primary human M-CSF
derived macrophages and RAWs, which are also known to exhibit the oxidative burst (174, 182).
Thus, it is important to consider that RAW macrophages are known to exhibit a poor oxidative
burst, owing to their heterogeneity in NADPH oxidase activation (201). Indeed, differences in
oxidative burst across these cell lines should be carefully investigated in order to determine
whether the intracellular survival of the menD mutant is dependent on its response to the
macrophage’s respiratory burst.
Additionally, USA300 ΔmenD has been shown to be more resistant to the oxidative burst than
WT, and USA300 ΔhemB (152). Therefore, this cannot explain why the menD mutant does not
replicate in THP-1s. Interestingly, another study investigating THP-1 macrophages infected with
SCVs of S. epidermidis suggests that SCVs of this species do not induce the macrophage’s
oxidative burst as much as the wildtype strain, therefore explaining their intracellular persistence
(123). My results may similarly reflect the diminished induction of THP-1 oxidative burst as a
result of SCV infection. Future studies should employ ELISA analysis of iNOS in the supernatant
of THP-1s infected with either the menD mutant or the WT, to determine whether the SCV results
in diminished inducible nitric oxide synthase levels compared to WT.
Alternatively, when trying to understand this growth phenomenon we can consider the fact that
the results obtained using USA300 ΔmenD are different in more ways than one when compared to
the those obtained from the other two strains. The menD mutant demonstrates a unique temporal
delay in intracellular replication in RAWs. At 12 hpi, the majority of the phagocytosed menD
mutant within the macrophage populations are killed. However, a small fraction of these
macrophages contains replicating bacteria. This fraction likely increases at 18-24 hpi, when
bacterial burden is comparable to that of the wildtype. Perhaps the results we see with THP-1
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macrophages are due to this delay in growth. In future experiments, THP-1 infections should be
repeated but prolonged to investigate whether the menD mutant is capable of growing as it does in
the other cell types.

4.3

How are these SCVs capable of overcoming their auxotrophy?

The hemB and menD SCVs are auxotrophs for hemin and menadione, respectively. Therefore, if
they are capable of growing intracellularly, they may either be accessing their required nutrient
from the intracellular environment or producing it through an alternative mechanism that does not
require the disrupted gene. In the literature, there is a widely accepted notion that SCVs persist
intracellularly in both non-professional and professional phagocytes (119, 120, 202). However,
only one study has shown that while the hemB mutant can proliferate similar to wildtype S. aureus
within THP-1 macrophages, the menD mutant cannot (196). One study claims that this
phenomenon is due to the intracellular presence of heme-like compounds, and the absence of
menadione (199). However, that cannot explain why I see intracellular replication of the menD
mutant in both RAW and primary human M-CSF derived macrophages. My results suggest that
SCVs cannot be described solely by their ability to persist statically within the host’s intracellular
environment. As SCV persistence is said to be responsible for chronic and recurrent infections,
their ability to replicate intracellularly demonstrates a need for the investigation of how SCVs
overcome their auxotrophy.
In this study, I focused on the menD mutant in particular when trying to understand how SCVs
overcome their auxotrophy within the intracellular environment. A previous study has shown that
when tissue culture media contains menadione, the menD mutant’s intracellular growth defect is
complemented (196). Therefore, I considered whether the menD mutant was acquiring nutrients
from the tissue culture media during infections. My initial growth experiments demonstrated that
the menD mutant did not grow in RPMI unless it was supplemented with menadione or FBS.
Therefore, I performed my infections in this chemically defined media. Despite this, the menD
mutant still grew intracellularly. Therefore, I investigated whether there were traces of FBS
leftover from the tissue-culture media used to culture the macrophages. My results showed that
this was in fact, not the case as the menD mutant did not grow in the assay conditions while in the
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absence of macrophages. Thus, I became interested in investigating whether the mutant was being
stimulated by the intracellular environment in some way to overcome its auxotrophy.
To continue investigating whether the menD mutant was acquiring nutrients from the intracellular
environment, I considered whether the macrophages themselves were supplying either menadione
or menadione precursors to the phagosomal bacteria. Since infections were performed in RPMI
and mammalian cells do not produce their own menadione, I reasoned that it was conceivable that
the macrophages had stored trace amounts of menadione from the original tissue-culture media
that they were seeded from. However, neither the menD or aroC mutant grew in cultures
supplemented with macrophage lysates, indicating that macrophages do not supply menaquinone
or menaquinone precursors to supplement the growth of ΔmenD. Additionally, I was curious to
see if the presence of bacteria in the extracellular milieu was stimulating these macrophages to
produce these precursors. However, macrophages exposed to heat-killed S. aureus did not produce
lysates that could supplement the growth of the menD mutant either.
With these results, I concluded that the intracellular growth of the menD mutant was not due to it
acquiring menadione from the intracellular environment but instead due to it producing menadione
through an alternative undisrupted mechanism. The phagosome undergoes dynamic changes in
redox activity and increasing acidity, thus I considered whether these conditions would stimulate
the growth of the menD mutant in chemically defined media. However, my results show that
neither increasing acidity or changes in oxygen availability could induce the growth of the mutant.
These results made me consider the complexity of the phagosome further.
If acidity or oxygen availability are important factors in the stimulation of the growth of the menD
mutant, perhaps they are part of a complex set of conditions that need to be present for the mutant
to initiate replication but are ineffectual on their own. Without completely recapitulating the
intraphagosomal conditions in a test-tube, it is difficult to determine whether this is the case or not.
To better understand the role that oxygenation and acidity play in this growth, NOX2 or V-ATPase
inhibitors could be used to treat the macrophages during infection to inhibit the production of ROS
and acidification of the phagosome respectively. However, work previously published by our lab
shows that the acidity of the phagosome is in fact required for the GraXRS regulated intracellular
survival of S. aureus (191). Similarly, Tranchemontagne et al. (2015) suggest that USA300 senses
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phagosomal conditions and adapts to the acidity through a key virulence regulator that allows for
its intracellular survival (203). These findings are corroborated by another study which shows that
the loss of the SLC4A7 bicarbonate transporter results in reduced phagosomal acidification,
resulting in impaired intracellular survival of USA300 (204). Additionally, a reduction in ROS
would result in a less microbicidal environment irrespective of the strain in question.
Next, I considered whether the intracellular growth of the menD mutant was due to its ability to
produce menaquinone through an alternative pathway which was somehow induced by the
intracellular environment. For example, the futalosine pathway is used by H. pylori to produce
menaquinone (187). This pathway is downstream of chorismate synthase, an enzyme that is also
upstream of the men pathway in USA300 to produce menaquinone. I had predicted that if this was
the case, performing gentamicin protection assays using USA300 aroC::ΦNΣ would demonstrate
that this mutant has an inability to grow intracellularly. However, USA300 aroC::ΦNΣ exhibits
the same eventual growth as the menD mutant. Therefore, intracellular growth of USA300 ΔmenD
is not due to an alternate menaquinone biosynthesis pathway downstream of chorismate synthase.
Both the hemB and menD mutants are unable to utilize the electron transport chain to produce
energy as heme and menadione are both required for aerobic and anerobic electron transport
phosphorylation. Transcriptomic and proteomic analyses of both S. aureus ΔmenD and ΔhemB
demonstrate that glycolysis, arginine deiminase fermentation pathway, and anerobic respiration
are upregulated, in comparison to the WT (127, 129). The arginine deiminase pathway is suggested
to increase SCVs ability to survive intracellularly because it produces ammonia to counteract the
phagosomal acidity, and generates ATP (127, 129). Additionally, the menD mutant has higher
expression of the arc operon genes involved in the arginine deiminase pathway (127, 129).
Interestingly, these transcriptomic and proteomic analyses suggest that the cellular membrane
potential, components of the electron transport chain, and the redox balance of NAD/NADH all
contribute to the regulation of anaerobic genes (127, 129). This could help to explain why these
SCVs are capable of surviving and replicating intracellularly, in the absence of the nutrients that
they require. They also help explain why these SCVs do not grow in RPMI alone in in vitro growth
experiments, because they must be activated by intracellular conditions.
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In comparing the menD and hemB mutant transcriptomic and proteomic analyses, three
mechanisms have been suggested to exist in S. aureus, which result in the upregulation of the
fermentation and anaerobic pathways during low oxygen conditions (127, 129). One of these
hypothetical mechanisms is dependent on menaquinone availability, and induces both the WT
under anaerobic conditions and the hemB mutant constitutively (127, 129). Although the
regulatory components remain to be identified for this mechanism, the genes in question were only
induced in the presence of menaquinone, which is promising support for the hypothesis (127, 129).
If this hypothetical mechanism does exist, it could potentially explain why the menD mutant
exhibits a delay in intracellular replication when compared to the hemB mutant in my study. While
the hemB mutant is also an auxotroph, it can conceivably initiate its intracellular replication sooner
than the menD mutant through using menaquinone to induce the genes for its anaerobic respiration.
Conversely, the menD mutant likely requires more time to react to the redox changes and oxygen
concentrations in the phagosome.
To investigate whether the arginine deiminase pathway is indeed necessary for the intracellular
growth of these SCVs, future studies should work towards creating an arginine deiminase
knockout in USA300 ΔmenD. Once this mutagenesis is complete, gentamicin protection assays
and eFluor-670-based proliferation assays must be performed to determine whether this mutant
can replicate intracellularly. If it cannot replicate, this would provide support for my hypothesis
that menD uses this pathway to produce ATP when triggered by the intracellular environment. To
determine if USA300 ΔhemB lacks the growth delay of the menD mutant because it utilizes
menaquinone to activate its anaerobic respiration, a hemBmenD double mutant should be
generated. Once again, the infection assays must be performed to determine whether this mutant
will exhibit the growth delay. If it does have the growth delay, this would provide support for my
hypothesis that the growth delay exhibited by the menD mutant is due to the time it requires to
induce its anaerobic respiration. Finally, phagocytosed SCVs should be recovered from
macrophages and used to inoculate RPMI. If these SCVs grow, it would provide support for my
hypothesis that they require the intracellular environment to initiate their anaerobic ATP
production which supports their replication.
If these experiments determine that the arginine deiminase pathway are not necessary for the
intracellular growth of the SCVs, I hypothesize that there may be an alternative pathway that is
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used to compensate for the disruption in the ETC. To investigate this, I began the process of
producing multiple ETC gene knockouts in the menD mutant. By disrupting either atpG or atpA,
ATP synthase function would be disrupted, essentially resulting in the uncoupling of ATP
synthesis and the electron transport chain. The two terminal oxidases encoded by qoxB and cydB
are heme dependent, and power the growth of S. aureus (128). In fact, a cydBqoxB double mutant
in S. aureus results in an SCV phenotype, and suggests an inability to utilize aerobic respiration
(128). Thus, I was in the process of producing this double mutant in the menD mutant background.
Examining the effects of either this uncoupling or complete disruption of oxidative
phosphorylation on the intracellular growth of the menD mutant could provide support for my
hypothesis, if these mutations do not have any effect on the growth of the mutant.

4.4

Does CFTR deficiency affect SCVs in the way that it effects WT USA300?

My results demonstrate the CFTR deficiency varied in the effects it had on the intracellular growth
of WT USA300. However, in the case of both SCV strains, the deficiency in CFTR does not appear
to have any significant effects on intracellular growth. When observing the bacterial burdens of all
three strains recovered from CFTR inhibitor-treated THP-1 macrophages, the inhibitor appears to
have a killing effect on the bacteria. Although, these observations are based on trends in the data
that are not statistically significant, these experiments should be repeated with more biological
replicates. Additionally, the minimum inhibitory concentration of this inhibitor should be
determined for each strain as well to assess whether its presence in the tissue culture media has
confounding effects on the bacterial burden. As I have described above when discussing WT
infected CFTR-deficient macrophages, future experiments must be performed to determine
whether CFTR-deficient macrophages exhibit inherent differences in intracellular trafficking and
the inhibition of bacterial replication.

4.5

Conclusion

In summary, S. aureus frequently colonizes the CF lung and due to its inherent antibiotic resistance
and its ability to form small colony variants, it increases the risk of morbidity and mortality for CF
patients. My work shows that MRSA and its small colony variants are phagocytosed by CFTRdeficient macrophages similar to otherwise normal macrophages. Once phagocytosed these
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bacteria survive and replicate intracellularly. CFTR deficiency does not have an effect on the
bacterial burden of SCVs, although it has varied effects on that of the WT dependent on the type
of macrophage infected. These results demonstrate the heterogeneity between macrophage types
frequently used in this field.
Importantly, my work shows that SCVs proliferate inside macrophages, which contrasts what has
been stated in the literature. These findings are interesting as they suggest that that despite the
long-held notion that SCVs evade immune detection by persisting intracellularly, SCVs can in fact
replicate and emerge from a subset of host macrophages. In the past, SCV persistence has been
used to suggest that SCVs are responsible for perpetuating chronic and recurrent S. aureus
infections. My data suggests that the interactions between SCVs and macrophages are more
complicated than static intracellular persistence, and therefore more research should be conducted
to investigate how SCVs are able to overcome there auxotrophy when inside host cells. These
investigations could further elucidate the role which SCVs play in chronic and recurrent infections.
What is more, my work discovers a unique growth delay for the menD mutant and demonstrates
that SCVs differ from each other and WT S. aureus in how they interact with macrophages. This
is important because further investigation of this growth delay could result in the elucidation of
the mechanism which underlies intracellular energy production for both SCVs and the WT S.
aureus. Together my work provides insight into the growth and survival of S. aureus and its SCVs
in CFTR-deficient and normal macrophages.
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